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CHAPTER I
ABSTRACT

Hepatitis C Virus (HCV) infects 170 million individuals worldwide. Although
several newly FDA approved drugs targeting the HCV serine protease and polymerase
have shown promising results, there is a need for better drugs that are effective in treating
all HCV genotypes and subtypes to be used in an interferon-free regimen. On the other
hand, malaria is another public health burden that causes 219 million clinical episodes,
and 660,000 deaths per year. In addition, 3.3 billion people live in areas at risk of malaria
transmission in 106 countries. It is alarming that 86% of deaths caused by malaria globally
were in children. Several challenges are faced when treating malaria, such as resistance
against drugs that are used in treatment. This necessitates the development of new classes
of drugs to overcome resistance.

CD81 is a target protein that plays an essential role in the internalization of HCV
into hepatocytes. Thus it was also targeted to identify sets of small molecule ligands
predicted to bind to several sites that were identified to be involved in HCV infection.
Thirty-six ligands predicted by AutoDock to bind to these sites were tested experimentally
to determine if they bound to CD81-LEL. Binding assays conducted using surface
Plasmon resonance revealed that 23 out of 36 of the ligands bound in vitro to the
recombinant CD81-LEL protein.
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In an effort to create new drugs that block hepatitis C virus entry into hepatocytes,
we have designed and synthesized a small molecule that targets the HCV E2 glycoprotein
binding site on CD81. A selective high affinity ligand (SHAL) (11) was created by linking
together two small molecules that were predicted by docking and were shown by
experimental methods to bind to the same site on CD81 where E2 binds. SH7153 was
found to bind to recombinant CD81-LEL with a Kd of 21 µM but wasn’t found to inhibit
HCV infection when tested using Raji cells (antibody neutralizing assays) and HCV
infection inhibition assays. This led to the conclusion that the linkers’ lengths should be
optimized so as to have a SHAL that fits properly in the desired binding sites.
The HCV glycoprotein E2 has also been shown to play an essential role in
hepatocyte invasion by binding to CD81 and other cell surface receptors. Recently, 2
research groups were able to resolve the core structure of HCV E2 which will largely help
providing structural information that can now be used to target the E2 protein and develop
drugs that disrupt the early stages of HCV infection by blocking E2’s interaction with
different host factors. By targeting conserved E2 residues among different genotypes and
subtypes in the CD81 binding site on HCV E2, one might also be able to develop drugs
that block HCV infection in a genotype-independent manner. Using the E2c structure as
a template, we have used homology modeling methods to develop a structural model of
the E2 protein core (residues 421-645) that includes the three amino acid segments that
are not present in the E2c structure. Blind docking to this model was then performed using
a library of ~4000 small molecules and a set of 40 ligands predicted to bind near conserved
amino acid residues involved in the HCV E2: CD81 interaction were selected for
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experimental testing. Surface Plasmon resonance was used to screen the ligands for
binding to recombinant E2 protein and the best binders were subsequently tested to
identify compounds that inhibit the infection of hepatocytes by HCV. One compound,
281816, inhibited infection by HCV genotypes 1a, 1b, 2a, 2b, 4a and 6a with IC50’s
ranging from 2.2 uM to 4.6 uM. Such inhibitors may represent a new paradigm for HCV
treatment. In an attempt to make 281816 more promising, a SHAL prototype was designed
using an analogue of 281816 (SH2216). It would be tempting to test the SHAL inhibitory
effect and compare it to the 281816’s inhibitory effect.
To date, human CD81 (hCD81) is the only human surface protein known to play
a role in the process by which sporozoites of several Plasmodium species infect human
hepatocytes. Blocking a human receptor that is exploited for the entry process of
pathogens has been proven to be a good strategy for fighting drug-resistant mutants.
Hence, we targeted the 21 amino acid stretch on CD81 large extracellular loop that was
found to be involved in Plasmosium yoleii invasion via virtual screening runs, preliminary
binding assays and sporozoite invasion assays. This led to the identification of 4 drug
leads that range between moderate and strong inhibitors of infection by Plasmodium yoleii
and Plamodium falciparum. Additionally one ligand was found to potentiate the invasion
of Plasmodium yoleii.
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CHAPTER II
LITERATURE REVIEW
Parts of the literature review are adapted from the M.Sc. thesis – By: Al Olabi,
Reem Rafik (2010-07-19) - The American University in Cairo “In silico design of
selective high affinity ligands against HCV using novel computational biology
tools”
A) Hepatitis C Virus
1. History
In early 1970s researchers discovered that there were more than the two known
serotypes of hepatitis, hepatitis A and B. A third type was discovered and it was called
none A non B (NANB) hepatitis. This discovery was a result of extensive work, which
began by monitoring the participants in the study analyzing an abnormal pattern of
aminotransferases bi-monthly for 6 to 12 months. This was followed by transfusion
studies that were an eye opener on acute hepatitis. It was believed that the transfusion
associated hepatitis would be hepatitis B but it wasn’t. This was proven when the samples
were found to be non-reactive to hepatitis B tests. The stored sera from the transfusion
studies were then used to inoculate chimpanzees, which later on developed biochemical
abnormalities (e.g. elevated aminotransferases) indicating that NANB type was a
transmissible agent. After 15 years of research, hepatitis C was identified by Houghton et
al. (1). Specific serological tests were developed and a comparison between NANB and
HCV confirmed that they are the same (2).
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2. HCV genomic diversity
There are six major genotypes of HCV worldwide with RNA sequences that differ
by >30 %. These genotypes are further classified into subtypes, isolates and quasispecies
(3). The continuous mutation of HCV is due to lack of efficient proof reading by the RNA
dependent RNA polymerase in addition to the lack of the 5’ to 3’ exonuclease activity
which leads to accumulation of mutations and viral escape (4). The host immune’s
response is one of the major factors that affect the persistence of HCV infection leading
either to viral clearance or to chronic infection. It is believed that there are positive and
negative selection processes in which the beneficial mutations are selected and favored
over deleterious ones (5). The HCV genotype is one of the most important predictive viral
factors for the response to therapy. Other factors affecting response to therapy include sex
and age of the patient, the initial viral load and the presence or absence of liver fibrosis
(4).
3. HCV Life Cycle
3.1.

Proposed model of HCV entry into hepatocytes
HCV entry into the host cells involves several host receptors such as CD81 (6,

7, 8), the tight junction protein Claudin-1 (CLDN-1) (6, 9), scavenger receptor class
BI (6, 8, 10). LDL-R (6, 8), mannose binding lectins DC-SIGN and L-SIGN (6),
heparan sulfate proteoglycans (11, 6) and the asialoglycoprotein receptor (6). LDL-R
and heparan sulfate play the initial role by mediating the attachment of HCV to CD81
and SRBI which upon interacting will trigger HCV movement and internalization via
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CLDN-1 and occludin (11). Figure 1 shows the proposed HCV entry mechanism (11,
12).
It was proposed that HCV particles become associated with low density
lipoproteins (LDL) and very low density lipoproteins (VLDL) leading to the
conclusion that LDL receptors are involved in the entry. Glycosaminoglycans (GAGs)
and LDL-R function as primary receptors that mediate the attachment of HCV to
CD81 and SR-BI (11, 12). CD81 and SR-BI in turn triggers HCV movement towards
the tight junction proteins; claudin-1 (CLDN1) and occluding (OCLDN) which act as
co-receptors (11, 12). The tight junction proteins act at a late stage of entry which is
followed by the internalization of HCV through Clathrin-mediated endocytosis. It was
suggested that HCV then moves inside the host cell in a low pH endosome where the
acidification of the endosome helps mediate an HCV glycoprotein: endosomal
membrane fusion (12, 13). It was found that the envelope proteins of other flaviviruses
and alphaviruses (such as Semliki Forest virus and Dengue virus) possess an internal
fusion peptide (class II fusion protein) that rearranges and trimerizes when exposed to
low pH. This led to an assumption that HCV could involve class II fusion proteins in
its internalization process (12).
3.2.

Polyprotein Synthesis
This step begins with the decapsidation of the HCV nucelocapsid releasing the

free positive stranded HCV genomic RNA which in turn acts as a mRNA with the newly
synthesized RNA. This is followed by the translation of the HCV genome which is IRES-
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dependent to produce the structural and nonstructural proteins needed for the completion
of the life cycle, assembly and infecting other cells (14, 15). A cap-independent internal
initiation of HCV polyprotein translation is mediated by IRES via recruiting both cellular
proteins, including eukaryotic initiation factors (eIF) 2 and 3 and viral proteins (16, 17,
18). It was found that the core protein and nonstructural proteins NS4A and NS5B alters
the IRES translational efficiency (19, 20).
3.3.

HCV Replication
Rearrangements of intracellular membranes are induced by the Infection with the

HCV positive-strand RNA virus and HCV NS4B protein was found to induce the
formation of the membranous web necessary for replication (21, 22). The membranous
web is derived from ER membranes (23). The membranous web consists of small vesicles
embedded in a membranous matrix, forming a membrane-associated multiprotein
complex that contains all of the nonstructural HCV proteins (21). HCV replication is
catalyzed by the NS5B RNA-dependent RNA polymerase (RdRp). The positive-strand
genome RNA serves as a template for the synthesis of a negative-strand intermediate of
replication during the first step. In the second step, negative-strand RNA serves as a
template to produce numerous strands of positive polarity that will subsequently be used
for polyprotein translation, synthesis of new intermediates of replication or packaging into
new virus particles (23).
3.4.

Virus Assembly and Release
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Initiation of virion assembly requires release of replicated genomes from the
endoplasmic reticulum to allow their contact with core protein, which forms the HCV
capsid. Assembly is thought to initiate in the cytosol before further maturation, and release
occurs by transfer of nascent particles across the ER membrane to enable access to the
secretory pathways in hepatocytes [24].
To sum up the assembly and release of HCV particles, it is divided into 3 stages
that are interconnected: (i) an initial phase of assembly at LDs, (ii) the contribution made
by viral factors that probably takes place after assembly has begun, (iii) and events on the
lumenal side of the ER membrane where there is engagement with the VLDL assembly
pathway to facilitate virion maturation and release (figure 2).
4. HCV Epidemiology
Hepatitis C virus infects around 200 million of the world population (figure 3). In
the developed countries, the chronic HCV infection accounts for 80% of the patients, and
acute HCV for 20%. 40% of the infected patients’ progress to end stage cirrhosis, 60% to
hepatocellular carcinoma and 30% require liver transplantation (25). Chronic hepatitis C
prevalence ranges from 0.1% to 14.5% in different countries (26) and Egypt has the
highest HCV prevalence worldwide (15%).
5. HCV genome and proteins

HCV is a positive strand-RNA virus possessing a genome of approximately 9.5
kilobases which encodes a large polyprotein containing 3010 amino acids (figure 4) (14).
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The processing and cleavage of the polyprotein is performed using the machinery of the
host and enzymes produced by the virus. Ten structural and non-structural proteins are
produced upon cleavage of the polyprotein. Either pathway involves peptidase cleavage
signals (27). There are two untranslated regions (UTRs) one at the 5’ end and one at the
3’ end of the RNA (figure 4) (28, 29).

The structural proteins are the envelope glycoproteins denoted E1 and E2 and the
core protein. There are two other proteins of unknown significance known as “p7” and
“F” proteins (28, 30). As for the non-structural proteins; they are denoted NS2, NS3,
NS4A, NS4B, NS5A, and NS5B (27, 30). The structural proteins are released by the host
machinery in the endoplasmic reticulum, whereas the non-structural proteins are released
following cleavage by NS2-3 and NS3/4A protease. The C terminus of the capsid protein
undergoes further processing triggered by a signal peptide peptidase (29).

Table 1 provides a brief description of the HCV proteins and their functions. Since
the main HCV targets in this phase are HCV E2 glycoproteins, and HCV NS3/4A
complex, the next few paragraphs will provide more details on their nature and function
(29).

6. HCV Envelope glycoproteins

E1 and E2 glycoproteins are type I transmembrane proteins that possess a Cterminal transmembrane domain and an N-terminal ectodomain that is N-linked to
glycans. The glycans were found to play a role in virus entry and glycoprotein folding
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(27). ). Since HCV envelope glycoproteins are highly glycosylated, carbohydrate binding
agents (CBA) such as cyanovirin-N might prove to be promising in blocking HCV entry
into the cells (31). Both proteins are cleaved from the polyprotein by host signal peptidase
cleavage (18). E1 and E2 form a natural non-covalent heterodimer that is retained in the
endoplasmic reticulum (ER) (27, 32). Their retention in ER contributes to HCV infection
conversion into the chronic form because it cannot be detected by the host immune system
and also proves that the virus is released from the host cells by budding and exocytosis
(27).

Several host receptors were found to be involved in HCV entry by either mediating
viral attachment such as LDL-R and heparan Sulfate (23) or by interacting with HCV E2
glycoprotein such as CD81 and scavenger receptor BI (SR-BI) (24-26). These interactions
trigger HCV movement to the tight junctions and its uptake by Claudin-1 and its uptake
via Claudin-1 and occludin (1). Two hypervariable regions (HVR) have been identified
in the HCV E2 glycoprotein sequence. HVR-1 is formed from the first 27 amino acids of
the E2 N-terminus (ectodomain), and it largely contributes to the escape of the virus from
the host immune response. HVR-1 has also been shown to modulate HCV entry. As for
HVR-2, it has been described as an HCV entry modulator (27, 32). Viral glycoproteins
such as HCV E2 are considered to be a promising target to generate drug against because
it plays an important role in host cell interaction and thus if blocked will dissect the HCV
life cycle in its earliest phase. HCV envelope glycoproteins are believed to belong to class
II fusion proteins according to the model created by Yagnik et al. (33). Recently, 2 new

12

studies were done that showed that HCV E2 doesn’t belong to the class II fusion proteins
as will be shown in the next section (38,39).

7. E2 Homology models and resolved peptides and crystal structures
There is no crystal structure available for HCV E2 glycoprotein, nor are there
reliable homology models except for that developed by Yagnik et al. (33). It is strongly
believed that developing a reliable model of HCV E2 will be considered a break through
because it will open another path for new category of anti-HCV drugs based on fragment
based drug design and selective high affinity ligands approach.

Yagnik et al. (33) applied several fold recognition methods (such as TOPITS and
THREADER2) to develop an HCV E2 model using the envelope protein E of Tick Borne
Encephalitis virus as a template. In addition they constructed two truncated E2 proteins
by PCR. These two proteins (N2 and H strains) were used in heparin and CD81 binding
studies. The aim of those binding studies was to map the results obtained from
experimental studies they performed onto their E2 model with the goal of identifying
important residues involved in 'E2:CD81 interaction and a heparin binding domain. The
results obtained in this study were also used to propose a rough model for the quaternary
structure of the envelope glycoproteins E1 and E2 complex (34).

The C-terminal ends of the E1 and E2 glycoproteins play important roles in E1E2 heterodimerization and retention in (ER). Charloteaux et al. (35) examined the Cterminal sequences of E1 and E2 in 25 HCV strains and used these sequences to generate
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several 3-D models. They found out that both domains of E1 and E2 should have a
configuration of one amphipathic α helix followed by a pair of transmembrane strands.
After generating 3-D models and minimizing the energy, the molecular hydrophobicity
potentials (MHP) calculation and the IMPALA procedure (a Monte Carlo minimization
of energy based simulation) were used to evaluate the C-terminal domains’ interaction
with the membranes. They concluded that the created 3-D models were consistent with
the experimental studies in that both C-terminal domains are involved in ER retention and
in E1-E2 heterodimerization (35).

Yu et al. (36) created a structural model of the HCV E2 protein using the Yagnik
et al. (33) sequence alignment. The template used was the crystal structure of the tickborne encephalitis virus (TBEV) soluble E protein. The ectodomain of HCV E2 in this
model was similar to that of domains I and II of TBEV E protein and HCV E1 glycoprotein
was similar to domain II of TBEV E protein. They proposed that E1 and E2 glycoproteins
form a tetramer that forms the basic building block of the outer shell of HCV where as in
case of flavivirus (TBEV) the outer shell is formed of E-protein dimers (36).

Spiga et al. (37) reported a 3-D structure for the HCV E2 homodimer that was
developed based on a secondary structure prediction using PsiPred. This was followed by
fold recognition using GenThreader v.2.1. software. They used both the TBEV E-protein
as a template and the alignment of the consensus sequence of six HCV E2 genotypes (1a,
1b, 2a, 2c, 3a, 4c) in building the E2 model using DeepView v.3.7 software. The model’s
sequence identity with the template was 14% and the structure exhibited little secondary
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structure (mainly B-sheets). In addition, molecular docking simulations were conducted
to predict the HCV E2 dimeric assembly. The aim of the study conducted by Spiga et al.
was to find surface exposed protein sequences that could be immunoreactive in the HCV
E2 glycoprotein (E2 mimotopes) and also common in most genotypes. Nine fragments
were selected in the developed model, synthesized on nitrocellulose membranes and tested
through binding assays using phosphate conjugated anti-HCV human antibodies. This
approach was considered important because it might be used to develop diagnostic kits
(37).

Recently, Kong et al. (38) and Khan et al. (39) have been able to resolve the crystal
structure of the core of the HCV E2 glycoprotein. Kong et al. (38) obtained the structure
of amino acid residues 384-746 (E2c) by designing and expressing 41 soluble HCV E2
constructs and selecting 15 to screen against E2-specific Fab fragments in crystallization
trials. Using a combination of x-ray crystallography and negative stain-electron
microscopy, Kong et al. (38) discovered that the structures they obtained for E2 were
globular and very different from the predicted models of E2 that were developed using
class II fusion protein templates containing three β-sheet domains (figure 5).

Additionally, they were able to identify key CD81-binding residues through
mutational studies. The CD81 binding sites were determined to be in the AR3C epitope,
along one side of the B-sandwich (an isolated region of the CD81-binding loop) and a
front layer consisting of loops, short helices and β-sheets (38). AR3C was also found to
cross-neutralize HCV genotypes by blocking CD81 binding to HCV E2 (38). On the other
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hand, the resolved structure of Khan et al. (39) were reported to be crystallized in complex
with a FAB fragment of the mouse monoclonal antibody 2A12, and it was found to be
highly similar to the previously reported structure (figure 6).

8. Significance of CD81 in HCV Infection
Several research groups have found that the CD81- large extracellular loop
(CD81-LEL) is the domain involved in HCV entry via interaction with HCV E2
glycoprotein (40,41). Higginbottom et al. (42) identified 4 amino acid residues that are of
large significance in the E2-CD81 interaction using mutational studies. They found that
the D196E mutation reduced the binding to E2. In addition mutations F186L and E188K
inhibited binding of CD81 to E2 whereas T163A enhanced their fusion (42). Drummer et
al. (43) identified an E2 binding site in CD81-LEL to occupy around 806 A°2. The most
important contact residues they found within this site were Ile182, Phe186, Asn184, and
Leu162 (43). The identification of these residues provides new targets for the design of
selective high affinity ligands that could inhibit E2-CD81 interaction. Zhang et al. (44)
also discovered a novel function for CD81 in HCV life cycle. They found that CD81 is
important for efficient HCV genome replication.
This same group also discovered that the E2-CD81 interaction had several
immuno-modulatory implications, among which include inducing in vitro a costimulatory signal in naive and antigen-experienced T cells leading to production of proinflammatory cytokine gamma interferon. Thus the CD81-E2 interaction might play a role
in T-cell-mediated liver inflammation and lead to liver damage. In addition, the interaction
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of these two proteins down regulates T cell receptors and suppresses the activity of natural
killer (NK) cells (43). Brazzoli et al. found out that CD81 is a central regulator for several
events within the HCV life cycle. CD81 was found to activate Rac, Rho, and Cdc42 (Rho
GTPase family) mediating the contact between HCV E2/CD81 complex with CLDN-1
and occludin tight junction proteins to internalize HCV into the cell. Thus inhibiting
CD81-HCV E2 interaction will block these events as stated and will massively reduce the
infectivity of HCV (figure 7) (45,46). Figure 7 illustrates the role of CD81 in disrupting
the host immune response against HCV. On the initiation of HCV infection, the CD81:
HCV E2 interaction on the surface of different immune cells leads to activation,
aggregation, increased survival of B cells and triggers VH gene hypermutation. This is
thought to cause the HCV-induced mixed cryobulinemia and non-Hodgkin’s lymphoma
(45). Additionally, this interaction leads to the activation of the protein tyrosine kinase
Lck which might be responsible for the presence of auto-reactive T cells in patients
infected with chronic HCV (45,46). On the other hand, the HCV E2: CD81 interaction
might also lead to the production of a ligand for the CCR5 receptor (RANTES) which
when ligates to CCR5 at the surface of pDCs ends in priming T cells and decreasing the
secretion of IFN-α and impaired maturation, proliferation and survival of these cells
(45,46). On the whole, impairment of pDCs and NK cell functions might explain the
establishment of chronic HCV infection (45).
To conclude the significance of CD81 in HCV infection, it is considered a key
player in regulating HCV life cycle where it controls the initiation of the infection. CD81
is also involved in triggering the host response due to HCV infection, in addition to the
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replication and dissemination of HCV. The significant functions that CD81 plays in HCV
infection are reviewed in (46).
9. HCV treatment
Sustained virologic response (SVR) is defined as “having no detectable viral RNA
after completion of antiviral therapy.” (47). The main aim of any anti-HCV treatment is
to achieve SVR since it is accompanied with better clinical outcomes, lower rates of HCVrelated morbidity and mortality, and stabilization of liver histology (47,48). The SVR was
assessed after the end of therapy by 6 months. Recently, the assessment is also done after
12 weeks of end of therapy so as to stop the treatment after 12 weeks if the SVR is
achieved (48).
The HCV Standard of Care (SOC) for many years was a combination of
peginterferon (PEG-IFN) and ribavirin (RBV) owing to it being the only FDA approved
combination therapy for HCV (49). This treatment was shown to have many side effects
that could lead to the non-adherence to the assigned regimen in addition to having
different rates of response to it depending on the HCV genotype and subtype.
Great efforts are being carried out to produce new drugs with higher efficacy, and
better patient compliance being of less side effects, frequency and route of administration.
The life cycle of HCV has several steps of interest that could be targeted and yield
promising classes of drugs. Among the classes that are being developed are NS3 protease
inhibitors, NS5B polymerase inhibitors, ribavirin analogs and cyclophilin inhibitors
(figure 8) (50). On the other hand, different research groups were working on resolving
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the structure of HCV E2 so as to help in creating anti-HCV vaccines and drugs by
targeting HCV E2. Additionally, there are several efforts done to target the entry stage in
the HCV life cycle through targeting the host factors involved in HCV entry into
hepatocytes that were discussed in the HCV life cycle section.
Drugs Targeting HCV (Directly Acting Antivirals “DAAs”)

9.1.

9.1.1. Protease Inhibitors
HCV serine protease has been extensively studied at the biochemical level and its
structure is known (51,52). The NS3 serine protease is located in the N-terminal region of
NS3 and is associated with the NS4A cofactor. Being one of the characterized HCV
proteins, it became a potential anti-HCV drug target. The NS3/4A protease inhibitors can
be divided into two chemical classes: macrocyclic inhibitors and linear tetrapeptide aketoamid derivatives.
Serine protease inhibitors range from being of low to high genetic barrier where
genetic barrier is the number of aminoacid mutations needed to confer resistance to the
drug used in treatment. The protease inhibitors of low genetic are more prone to HCV
resistance needing only single mutation in the HCV particle whereas those of high barrier
are less prone to resistant HCV strains since they need more than one mutation (53).
Simeprevir is the newly FDA approved oral protease inhibitor (50). Its efficacy has been
established in combination with peginterferon alfa and ribavirin in patients with HCV
genotype 1 infection with compensated liver disease (including cirrhosis). In Table 2, the
current protease inhibitors that are in different clinical phases, the manufacturing
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company, the chemical structure being linear or macrocyclic, the genetic barrier, the
required dose per day, their IC50 values, and the genotypes they are active towards are
enumerated (53).
9.1.2. Polymerase Inhibitors
Polymerase inhibitors bind to NS5B RNA-dependent RNA polymerase. NS5B
RNA interfering with the viral replication. They are categorized into 2 different types:
nucleoside inhibitors (NI) and non-nucleoside inhibitors (NNI). NI mimic the natural
substrates of the polymerase thus incorporated into the RNA chain causing direct
chain termination (54, 55). They require conversion to an active triphosphate form.
On the other hand, NNI bind to several discrete sites outside of the HCV polymerase
active center, resulting in conformational changes in the HCV polymerase before the
elongation complex is formed (54,55). Sofosbuvir is the most significant newly FDA
approved oral HCV drug and polymerase inhibitor. Sofosbuvir is used in combination
with ribavirin or ribavirin plus interferon to treat HCV genotypes 1,2,3 and 4.
9.1.3. NS5A Inhibitors
The NS5A is a membrane-associated phosphoprotein in the HCV genome,
which is present in phosphorylated (p56) and hyper-phosphorylated (p58) forms (55–
57). It is involved in HCV virion production and has significant roles at various stages
of HCV life cycle. NS5A has been shown to play a role in conferring resistance to
interferon via interaction with a number of host proteins in vivo (55, 56). Daclastavir,
an NS5A inhibitor, was found to be active at picomolar concentrations in HCV
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replicons expressing a broad range of HCV genotypes (55–57). Accordingly, it might
be another holy grail in the field of HCV treatment.
9.1.4. Targeting HCV E2 to develop anti-HCV drugs and vaccines
Several approaches are being used to develop anti-HCV drugs and vaccines that
target the HCV E2 glycoprotein. Developing monoclonal and polyclonal antibodies is one
of the approaches used. XTL Biopharmaceuticals reported that a combination of the
monoclonal antibodies AB68 and AB65 (AB6865) was more effective than each one
alone (58). Both monoclonal antibodies were obtained by immortalizing peripheral blood
mononuclear cells obtained from the blood of HCV infected patients. It was observed that
AB6865 combination can identify different conformational epitopes on E2 and immuneprecipitate different strains of HCV particles. The viral clearance takes place upon
formation of immune complexes by endocytosis since that AB6865 induces phagocytosis
of the immune complexes by neutrophils (58-61).
Bavituximab® is another monoclonal antibody developed by Peregrine
pharmaceuticals that acts against a unique target, phosphatidyl serine. Phosphatidylserine
is a lipid molecule normally found in the interior of cellular membranes and becomes
exposed on the cell surface of cell membranes of viruses and host infected cells during
replication. It has been reported that the presence of the phosphatidyl serine on the surface
of the membranes of viruses creates a masking effect and thus helps the virus to evade the
host immune response. This monoclonal antibody can be used against several viruses such
as HIV, CMV, influenza and HCV. When comparing Bavituximab with other monoclonal
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antibodies, it was found to be more advantageous because it has high specificity towards
cells infected with viruses only. In addition it targets a molecule in the host and thus won’t
be affected by any viral mutations (62, 63).
Human hepatitis C immune globulin or Civacir is a polyclonal antibody obtained
from human plasma enriched with HCV polyclonal antibodies collected from screened
donors. It is used to prevent the re-infection of HCV infected patients who had a liver
transplant (64).
Another approach is to develop a vaccine that triggers passive immunity against
HCV. It was found that immunoglobulin G obtained from HCV infected patients could be
a good candidate for developing such a vaccine. Vanwolleghem et al. (64) injected 8
chimeric mice with immunoglobulin G obtained from HCV infected patients, which were
then challenged with 100% infectious dose of the acute phase HCV. Five out of eight mice
developed immunity against HCV. Law et al. (65) were able to isolate polyclonal
antibodies that bind specifically to HCV E2 and neutralize several HCV strains. Full
length immunoglobulins G were obtained from 3 antibody-antigen binding fragments that
bound to 3 antigenic regions on E2. Monoclonal antibodies were obtained from these
immunoglobulins and were injected intraperitoneally in mice with high levels of human
liver chimerism. These mice were then challenged by HCV infected human serum, but
the monoclonals didn’t show the desired effect (65).
A third approach involves carbohydrate binding agents (CBA) against HCV E2.
Since HCV envelope glycoproteins are highly glycosylated, carbohydrate binding agents
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(CBA) such as cyanovirin-N might prove to be promising in blocking HCV entry into the
cells (66). Several host receptors were found to be involved in HCV entry by either
mediating viral attachment (such as LDL-R and heparan sulfate) (67) or by interacting
with HCV E2 glycoprotein (such as CD81 and scavenger receptor BI (SR-BI)) (68-70).
Based on these findings new approaches were opted such as developing small molecules
that mimic the D-helix of CD81 and is known to interact with HCV E2 (71).
9.2.

Drugs Targeting Host factors at the entry level
HCV entry inhibitors target the first steps of HCV life cycle. Several studies

showed that they efficiently inhibit cell to cell transmission which is one of the significant
contributors to the spread of the virus throughout the liver. This makes this class of drugs
suitable for preventing liver graft infection which increases the rate of success of liver
transplantation. On the other hand, there are other host factors that are involved in the
immunomodulatory mechanisms that is controlled by HCV. They could be promising
targets as well. What makes targeting host factors of potential interest is the high genetic
barrier to resistance of some DAAs (72).
9.3.

Targeting CD81-LEL to develop anti-HCV drugs

Several research groups have found that the CD81- large extracellular loop
(CD81-LEL) plays a key role in HCV entry into cells by binding to the HCV E2
glycoprotein (10, 42, 73). Higginbottom et al. (42) and Drummer et al. (43) used
mutational studies to identify residues that contribute to the E2-CD81-LEL interaction
42). This information is important because it can be used to direct the design of a series
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of selective high affinity ligand-based inhibitors that block the E2-CD81-LEL interaction.
(42,43). Zhang et al. (44) discovered a separate, additional function for CD81 in the HCV
life cycle. These studies showed that CD81-LEL is important for efficient HCV genome
replication where the level of CD81 expression was found to modulate the HCV RNA
replication.

In addition, E2-CD81-LEL interaction induces several immuno-modulatory
effects, including co-stimulatory signal in naive and antigen-experienced T cells that leads
to the production of pro-inflammatory cytokine gamma interferon. Thus the CD81-E2LEL interaction may play a role in T-cell-mediated liver inflammation and contribute to
liver damage. In addition, the interaction of these two proteins down regulates T cell
receptors and suppresses the activity of natural killer (NK) cells (43). Meuleman et al.
(74) showed that using anti-CD81 as a prophylactic treatment completely protected
human liver-uPA-SCID infection with different genotypes of HCV (74).

9.4.

Other host factors Entry Inhibitors

HCV entry is considered one of the potential targets for creating an anti-HCV drug.
Several host factors are involved in the entry of HCV into hepatocytes. Intervening with
such mechanisms and blocking it might help in preventing both invasion of the virus, and
cell to cell transmission. Table 3 enumerates several classes of entry inhibitors that target
different host factors (72).
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11. Tables
Table 1. HCV proteins. This table shows the 10 HCV proteins, their molecular mass and
their function.
Protein

Molecular mass
KDa

Function

Core

21

RNA binding, nucleocapsid

E1

31-35

Envelope glycoprotein, associate with E2

E2

70

Envelope glycoprotein, associate with E2, receptor
binding

P7

7

Ion channel

NS2

21

Component of NS2-3 proteinase

NS3

69

N-terminal proteinase domain/ C-terminal
NTPase/Helicase domain

NS4A

6

NS3/4A proteinase co-factor

NS4B

27

Induces membrane alterations

NS5A

56-58

Phosphoprotein

NS5B

68

RNA dependent RNA polymerase
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Table 2. HCV protease inhibitors in different clinical phases (50).
Protease
Inhibitors

Company

Clinical
Phase

Chemical
Structure

Boceprevir

VICTRELIS
™ Merck

Linear

Telaprevir

INCIVO™
Janssen

Simeprevir

OLYSIO™

FDA/E
MA
approve
d
FDA/E
MA
approve
d
FDA/E
MA
approve
d

Faldaprevir

Boehringer
Ingelheim

3

BI-201 135
Danoprevir

Roche

2
2

MK5172

Merck

2

Sovaprevir
ACH-1625
Asunaprevir

Achillion

2

BMS

2

Required
Dose per
day
800 mg
TID

Genetic
Barrier

IC50
(nM)

Genotypes

Low

600

1,2

Low

300

1,2

Linear

1125 mg
BID

Macrocycli
c

150 mg QD Moderat
e

1-10

1,2,4,5,6

Macrocycli
c

120 mg or
240mg
QD
240 mg QD
200/r mg
BID
100/r mg
BID
50/r mg
BID
100/r mg
BID
100 mg QD

Moderat
e

1-10

1,2

Moderat
e

1-10

1,2,4

High

1-10

1,2,4,5,6

200-800mg
QD
200-600mg
BID
600mg BID
+
Daclatasvir
60mg QD

Moderat
e
Moderat
e

1-10

1

1-10

1,4

Macrocycli
c

Macrocycli
c
Macrocycli
c
Macrocycli
c
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Table 3. HCV Entry Inhibitors. This table shows the different host targets, the
corresponding examples of inhibitors and the stage of development of those inhibitors (72).
Target
CD81

Examples of compounds
(Cluster

of Anti-CD81 mAbs

Stage of development
Mouse model

Differentiation 81)
Imidazole based compounds
SR-BI

(Scavenger ITX5061

Cell culture
Phase I/IIa

Receptor – BI)

CLDN1 (Claudin – 1)

Anti-SR-BI mAbs

Mouse model

Serum amyloid A

Cell culture

Anti-CLDN1 mAbs

Cell culture

EGFR (Epidermal Growth Erlotinib

Phase I/IIa

Factor Receptor)
NPC1L1

(Neimann-Pick Ezetimibe

Mouse model

C1-Like 1 gene)
TfR1

(Transferrin Anti-TfR1 mAbs

Cell culture

Receptor Protein 1)
Post-attachment

Flavonoids

Cell culture

Fusion/internalization

PS-ON (Phosphorothioate

Mouse model

oligonucleotide)
Cell culture
Arbidol
Cell culture

33

Chloroquine

Silymarin

Cell culture
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12. Figures

Figure 1. HCV entry mechanism. LDL-R and Glycosaminoglycan plays the initial role
by mediating the attachment of HCV associated with liporptoeins to CD81 which then
interact with SR-BI triggering HCV movement to the tight junction proteins; claudin-1
(CLDN1) and occluding (OCLN) followed by clathrin mediated endocytosis (11, 12).
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Figure 2. Model for HCV virion assembly. Based on current evidence, assembly
initiates on the cytosolic side of the ER membrane (A), and complete maturation occurs
in the ER lumen (B) prior to release from the cell (24). (RC: Replicase Complex, LVP:
Lipo-Viro-Particles, MTP: Microsomal Triglyceride Transfer Protein)

36

Figure 3. Worldwide HCV prevalence
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Figure 4. HCV Genome. HCV genome is a 9.3 kb polyprotein divided into 3
structural proteins and 7 non-structural proteins (75).
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Figure 5. The E2c crystal structure resolved by Kong et al. This figure shows the
structure of the HCV envelope glycoprotein E2 core bound to the neutralizing
antibody AR3C (PDB ID: 4MWF) (38).
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Figure 6. The crystal structure of HCV E2 resolved by Khan et al. This figure
shows the structure of the E2 core domain in complex with an antigen-binding
fragment (Fab) at 2.4 Å resolution. The E2 core has a compact, globular domain
structure, consisting mostly of β-strands and random coil with two small α-helices.
The strands are arranged in two, perpendicular sheets (A and B), which are held
together by an extensive hydrophobic core and disulphide bonds. (PDB ID: 4NX3)
(39)
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Figure 7. Role of CD81 in disrupting HCV-induced immune functions (46). During
HCV infection, HCV E2 glycoprotein interacts with CD81 at the cell surface of different
immune cells which in turn leads to B cell activation, aggregation, and increased survival.
On the other hand, the interaction of HCV E2 with CD81 on T leads to the activation of
protein tyrosine kinase Lck. This interaction leads to the production of RANTES, a ligand
for the CCR5 receptor and which upon ligation to CCR5 at the surface of pDCs leads to
its internalization prevents its migration from infected tissues to lymph nodes. The direct
interaction of HCV E2 with CD81 at the surface of pDCs leads to a decreased secretion
of IFN in addition to impaired maturation, proliferation and survival of these cells. HCV
infection causes an impairment of NK cell functions. The role of CD81 in NK cell-altered
function could lead to a decreased IL-12- dependent IFN-γ secretion and an increased
secretion of IL-8.
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Figure 8. Different classes of HCV drugs targeting different parts of the HCV
genome. The main 3 classes of drugs that are currently studied are protease
inhibitors, NS5A inhibitors and polymerase inhibitors which are either nucleoside or
non-nucleoside polymerase inhibitors (50).
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B) Malaria

1. History

Malaria is considered one of the major parasitic diseases which is transmitted by
female Anopheles mosquito. It is caused by protozoan parasites belonging to the genus
Plasmodium (1). Malaria in human is caused by four types of Plasmodium sp. which are:
Plasmodium malariae, Plasmodium ovale, Plasmodium vivax and Plasmodium
falciparum. Plasmodium falciparum and Plasmodium vivax are the two major species
involved in the global malaria burden (1). Malaria infection starts by the invasion of the
parasite into the hepatocytes (liver stage) followed by invading the red blood cells of the
host (blood stage) (figure 1).

Malaria was productively studied since the 1880. Plasmodium falciparum has
existed for 50,000–100,000 years but the population size of the parasite increased only
since 10,000 years ago (2). The causative agent of malaria was discovered by Charles
Laveran (3). He discovered it through examining the blood smears of infected patients in
1884 (3, 4). In 1898, Scottish physician-Sir Ronald Ross, was able to reveal the complete
life cycle of malaria and proved the vector was a mosquito. He was awarded the Nobel
Prize based on his work in 1902 (5). Malaria antigen was detected in skin and lung samples
of Egyptian mummies in the years 3200 and 1340 BC (6,7).
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2. Diagnosis

Malaria is diagnosed mainly by the microscopic examination of the blood film to
view sporozoites and merozoites. Other techniques used are antigen-based rapid
diagnostic tests (RDT) (8, 9). The immune chromatographic tests (ICT) for the detection
of malaria are based on the same concepts of Enzyme Linked Immunosorbent Assay
(ELISA) and detect antibodies in blood or other body fluids (10, 11).
Malaria doesn’t yield characteristic symptoms when infecting a person.
Accordingly, when there a is suspicion of infection, recent travel history, fever, low
number of platelets, enlarged spleen, and higher-than-normal levels of bilirubin in the
blood combined with a normal level of white blood cells might help decide whether there
is a risk of malaria infection or not (12).

3. Current treatment

The treatment of Malaria depends on the type and severity of the disease.
Artimisinin-combination therapy (ACT) is considered the first-line therapy for
uncomplicated Plasmodium falciparum malaria worldwide (13). To date, there is no
enough data to help observe the emerging problem of ACT-resistant strains, hence there
is a need to study the dynamics of parasite clearance in people treated with ACT in order
to be able to confirm the emergence of artemisinin resistance (14).
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4. CD81: Malaria host receptor
The life cycle of Malaria starts through injection of sporozoites into the host’s skin
by female Anopheles mosquitoes. The sporozoites are motile due to possessing
actonyosin motor machinery which help them move in the blood stream, entering the liver
in and transform to liver stages in the hepatocytes. The motile sporozoites enter the blood
stream and, upon reaching the liver, transform into liver stages (14). They invade hepatic
parenchymal cells and produce exo-erythrocytic forms (EEFs) through a period of asexual
reproduction followed by infecting the erythrocytes causing the malaria disease (15, 16).

Silvie et al. (16) showed that CD81 is involved in the hepatic development of
Plasmodium falciparum and Plasmodium yoelii in the liver cells and in CD81-deficient
mouse hepatocytes, Plasmodium yoelii can’t initiate the infection process. Additionally,
they were able to show that antibodies against human and mouse CD81 blocked the
infection with Plasmodium falciparum and Plasmodium yoelii respectively. They were
able to prove that CD81 is involved in the entry stage of sporozoites into the liver though
being linked to the formation of parasitophorous vacuole which one of the major steps
needed for the sporozoites to transform to EEFs.
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6. Figures

Figure 1. Malaria Life cycle. The life cycle of malaria is divided into 3 significant
stages; The Exo-erythrocytic stage /Liver stage (A), the erythrocytic stage/Blood stage
(B) and the sporogenic stage which takes place in the gut of the female Anopheles
mosquito followed by its salivary gland (Center of Disease Control and Prevention)
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C) Summary and Conclusion

HCV and Malaria are two challenging infectious diseases due to the genomic
diversity and not having the full picture of the mechanism of entry into the host cells in
case of the former and the emerging resistant strains against the currently available
medications for the later. Several research groups identified important residues in CD81LEL involved in the infection of both HCV and malaria and their internalization into
hepatocytes (16, 43, 44). Targeting the identified residues would help develop promising
drugs for treating HCV and malaria.

Additionally, HCV E2 core crystal structure was recently resolved (PDB ID:
4MWF) (figure 5) (38). This would facilitate creating a reliable homology model for the
whole HCV E2 protein that could be used to identify drug leads that blocks HCV E2: Host
factors interaction.

Targeting HCV to develop drugs is advantageous because the side effects that
might be caused when using drugs that target host receptors are unpredictable. On the
other hand, targeting the host receptors to develop new classes of drugs is better when
dealing with the continuous mutation of HCV and the resistance it develops against direct
acting antivirals.

Different approaches could be used to generate promising drugs against HCV and
malaria. Generating selective high affinity ligands is one of them where it is mainly
linking to ligands that were found to bind to the target protein together to increase their
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binding affinity and it might reach a nanomolar binding affinity. Another one is to identify
a drug lead, optimize its chemical QSAR to be more effective with less side effects. Also,
finding different analogues to the drug lead, testing them and creating a library would be
a potential tool in the drug discovery process.
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CHAPTER III
IDENTIFICATION OF LIGANDS THAT TARGET HCV E2-BINDING SITE
ON CD81-LARGE EXTRACELLULAR LOOP
This chapter was published: Olaby, R. A., Azzazy, H. M., Harris, R., Chromy, B.,
Vielmetter, J. and Balhorn, R. (2013).Identification of ligands that target the HCV-E2
binding site on CD81. J. Comput. Aided Mol. Des. 27, 337-346.
Objectives
The purpose of this study was to screen a library of 10,000 compounds to identify
virtual screening hits that binds to significant sites on CD81-LEL. Additionally, it aimed
at testing the top virtual screening hits experimentally using Lab on a chip techniques to
help identify possible ligand candidates to be incorporated into a SHAL prototype. The
computational biology work was done at Scripps Research Institute, Dr. Arthur Olson’s
Molecular Graphics Laboratory, the dual polarization interferometry binding assays were
done at UC Davis at Dr. Brett Chromy’s lab, and the surface plasmon resonance binding
assays were done at Caltech at Dr. Jost Vielmetter’s protein expression center.

1. Introduction

The World Health Organization has estimated that approximately 3% of the world
population has been infected with Hepatitis C virus (HCV) and that more than 170 million
of these individuals are at risk for developing liver cirrhosis or cancer (1). The lack of
effective treatment or prophylactic vaccines makes HCV a serious public health problem.
The virus is a blood borne pathogen that is transmitted mainly through transfusions and
hemodialysis. During HCV replication, the post-translational processing and cleavage of
the virus polyprotein produces ten structural and non-structural proteins. The crystal
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structures that have been determined for a number of these proteins are being used to
facilitate both drug and vaccine development (2-9).

Several cell surface receptors have been suggested to play a role in HCV entry into
hepatocytes (10). These include LDL-R, heparan sulfate (11), scavenger receptor class BI
(SR-BI) and CD81 (12,13). Pileri et al. was the first to identify CD81, a 26 kDa protein
that belongs to the tetraspanins super family, as an important HCV receptor (14). While
this protein mediates the invasion of hepatocytes by HCV, it is also widely expressed in
both lymphoid and non-lymphoid tissues. CD81 contains six structural domains, four of
which are trans membrane domains and two are hydrophilic extracellular domains that
make up the large and small extracellular loops (15).

One reason CD81 has become such an important target for drug development is
because the large extracellular loop of CD81 (CD81-LEL) has been shown to bind to the
HCV E2 glycoprotein (16-19). Zhang et al. discovered that CD81-LEL is also important
for efficient replication of the HCV genome (18). In addition, the E2:CD81-LEL
interaction has been reported to induce several immuno-modulatory effects, including a
co-stimulatory signal in naive and antigen-experienced T cells in vitro that leads to
production of the pro-inflammatory cytokine α-interferon. This suggests that the
E2:CD81-LEL interaction may play a role in T-cell-mediated liver inflammation and may
contribute to liver damage. The interaction of these two proteins also appears to down
regulate T-cell receptors and suppress the activity of natural killer cells (18).
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CD81’s participation in cell invasion and its contribution to liver damage make it
an important target for new anti-HCV therapeutics. Some of the first inhibitors designed
to block the E2:CD81-LEL interaction were CD81 mimics developed by
VanCompernolle et al. (20). Small molecules were designed to mimic the solvent exposed
hydrophobic ridge of helix D in the CD81-LEL domain and were found to bind HCV E2
reversibly and to competitively block the binding of E2 to CD81 (20). This was the first
direct demonstration that CD81 is an important receptor in HCV entry (20). In addition,
the mutational studies conducted by Higginbottom et al. (17) and Drummer et al. (19)
identified the key amino acid residues that contribute to the E2:CD81-LEL interaction.

Kitadokoro et al. determined the 3D structure of CD81-LEL using X-ray
crystallography, and two different crystal forms of CD81-LEL (PDB codes 1G8Q and
1IV5) were reported (21,22). In the 1G8Q structure the C and D helices form a cleft-like
motif within the E2 binding site, a large cavity considered to be an excellent target site for
inhibitor development. The 1IV5 conformation, in contrast, was considered to be a closed
form of the CD81 structure in which this cleft is absent. Ligands binding to the closed
conformation would involve interactions with 1IV5 in more shallow surface exposed sites
than those present on 1G8Q (22). Molecular dynamics studies performed by Neugebauer
et al. (23) have been used to suggest that the 1IV5 structure may be the physiologically
relevant conformation. This conclusion has been attributed in part to the closure of the
cleft in 1G8Q that occurred during a 50 picosecond molecular dynamic simulation. The
1G8Q conformation with the open cleft was also considered to be less stable because more
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amino acid residues were found to be outside the favored energy region of the
Ramachandran plot. Further analysis of the two structures suggested that the cleft
observed in the open 1G8Q conformation might represent a distortion in the structure of
the protein induced by crystal packing. In the closed 1IV5 structure, two of the four alpha
helices (C and D) in CD81-LEL were observed to form a helix bundle with the two other
helices (A and B) of an adjacent molecule in the lattice. In the 1G8Q form, a different
interaction was observed between helices that appeared to distort the structure of the
protein and create the cleft (22).

The discovery of these two distinct crystal forms of the CD81-LEL protein with
very different surface structures in and around the E2 binding site has complicated the
process of inhibitor development. The “open” form has multiple cavities surrounding the
key amino acids, while the surface of the “closed” form has many fewer and shallower
sites where ligands might bind. While it has been suggested that the closed form may be
more stable than the open form, Neugebauer et al. (23) also indicated that the C and D
helices exhibit a certain degree of flexibility that might make it possible to identify small
molecules that fit inside the cleft between these two helices and block the interaction
between CD81 and E2.

In an effort to test that possibility, we have used AutoDock and AutoLigand to
screen a library of 10,000 small molecules in silico and identify ligands predicted to bind
to two sites on the open conformation of CD81-LEL, the large cleft between the C and D
helices and a smaller cavity located nearby. Both cavities are located within the E2
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binding site and in close proximity to five of the amino acid residues reported to contact
E2. Experimental methods have been used to test the best virtual screening hits for binding
to a recombinant form of CD81-LEL, and a set of new small molecule drug candidates
have been identified that bind to the protein. One of these compounds has been found to
block E2 binding to CD81-LEL. Fragment-based extension methods will be used to create
second-generation lead compounds from a number of these molecules. Others will be
linked together to create selective high affinity ligands (SHALs) (24) that target the E2
binding site on CD81-LEL and block HCV invasion.

2. Materials and Methods
2.1.

Preparation of CD81-LEL Structure and Prediction of Binding Sites
The AutoDock suite of programs developed by Dr. Arthur Olson’s molecular

graphics laboratory at the Scripps Research Institute was used to analyze the large
extracellular domain of our target protein CD81, prepare surface grid maps, and dock a
library of small molecules into cavities located in the vicinity of amino acid residues
known to participate in E2 binding (25-29).
The coordinates for the crystal structure of the open conformation of CD81-LEL
(PDB ID: 1G8Q) were obtained from the Protein Data Bank (PDB). AutoDock Tools
(ADT) 1.5.6 (25-28) was used to delete water molecules, add polar hydrogens, assign
Gasteiger charges, and create grid bounding boxes with a 1 Å spacing for use with
AutoLigand and a 0.375 Å spacing for use with AutoDock 4.2. AutoGrid 4.2 was used to
pre-calculate grid maps of interaction energies for various atom types and create the map
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files that were used by AutoLigand to predict the CD81-LEL binding sites and by
AutoDock for docking. AutoLigand was then used to rapidly scan the protein for high
affinity binding pockets and identify the optimal volume, shape, and best atom types for
each binding site.

The CD81-LEL protein was scanned by AutoLigand using fill sizes from 10 to
210 fill points. During this process, the structure (amino acid re

-carbon

backbone) was kept rigid. The constructed grid box enclosed the entire protein with
dimensions of 40 Å by 18 Å by 38 Å and was centered on 3.144, 34.966, and 15.812 in
the protein frame of reference. Five potential ligand binding sites were identified on the
open CD81-LEL structure (PDB code 1G8Q). Two sites located adjacent to amino acid
residues critical for E2 binding were selected for docking.

2.2. Virtual Screening

AutoDock 4.2 (25-28) was used to perform virtual screening runs using a subset
of the ZINC small molecule database containing 10,000 molecules taken from the
National Cancer Institute-Diversity Set II (NCI_DSII), Sigma, and Asinex libraries. The
parameters were set at 100 for the number of genetic algorithm (GA) runs, 150 as the
population size, and a maximum number of generations of 25000. The Lamarckian genetic
algorithm in AutoDock was used to perform the docking experiments (30). Docking
results were sorted by the lowest binding energy in addition to specific ligand selection
criteria that would facilitate the design and synthesis of the best SHALs. The virtual
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screening runs were performed using the National Biomedical Computation Resources
(NBCR) computer cluster (31). Vision (32) was used to construct the computational
workflows that were used for virtual screening on the NBCR cluster. The list of small
molecules predicted to bind to each site (~ 350 compounds) was ranked according to their
predicted free energy of binding, and the molecules with the lowest free energies were
further screened manually to identify ~120 of the best ligand candidates for experimental
testing.

2.3. Ligand Evaluation

Several criteria were considered as we examined the structures of each of these
~120 small molecules and selected a subset for subsequent experimental testing and for
use in the design of second-generation lead compounds and SHALs. All the molecules
selected could be purchased from chemical suppliers or obtained from the Developmental
Therapeutics Program at NCI. During the initial examination of the list of ligands
predicted to bind to each site by AutoDock, only molecules containing a free carboxyl
group or an amino group (or one of each) were selected. In the most highly ranked cases,
these amino or carboxyl groups were not buried in a cavity nor did they interact with the
protein surface. They were exposed to solvent and were predicted by AutoDock to bind
to the protein with the functional group pointed in the general direction of the second
ligand binding site. Such molecules could be easily linked together through their amino
or carboxyl groups to create SHALs (24). Preference was given to ligands that were
predicted to form multiple contacts with atoms or amino acid residues in or around the
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perimeter of the targeted cavities. Molecules that were highly hydrophobic, highly
charged, known to be toxic, exist in more than one form (such as enol-keto forms), or
contained disulfide bonds were avoided. After manually filtering the ligand sets to remove
the molecules that did not meet these criteria, the predicted binding energy was used to
identify the top hits. Thirteen molecules predicted to bind to Site 1 were selected from
this group for experimental testing and 23 molecules were selected for Site 2. Small
amounts (10mg) of these 36 compounds were then obtained from the National Cancer
Institute (Diversity Set II small molecule library) and tested experimentally for binding to
the CD81-LEL protein.

2.4. Surface Plasmon Resonance

SPR analysis was performed using a Biacore T200 workstation (GE Healthcare,
NJ, USA). A recombinant form of the CD81-LEL protein with a GST tag (generously
provided by Dr. Shoshana Levy, Stanford University) was used to determine, using well
established experimental technique, if the ligands bound to the protein. Briefly, 10 µM
CD81-LEL-GST diluted into 10 mM Na-Acetate buffer pH 4.5 was immobilized for 15
min at a flow speed of 5 µl/min onto a CM5 sensor chip using amine-coupling (EDCNHS). Approximately 20,000 RU of protein were immobilized on the chip. The ligands
were prepared as 600 µM solutions in PBS-0.05% Tween-80 (the running buffer) and they
were introduced to the protein using a pre-programmed 3 minute association and 1 minute
dissociation interval.
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The binding affinity of selected ligands were estimated using data collected from
a series of SPR binding experiments conducted at different ligand concentrations. To
obtain the kinetic and affinity data needed to estimate the Kd, the original ligand sample
was diluted serially with running buffer to produce seven different ligand concentrations:
1024 µM, 516 µM, 256 µM, 128 µM, 64µM, 32 µM and 0 µM. Data were fitted using a
monovalent binding model.

2.5. Dual Polarization Interferometry (DPI) Analysis

DPI analyses were performed using an AnaLight 4D workstation (Farfield Group,
Manchester UK). The recombinant CD81-LEL was immobilized onto a Thiol AnaChip
using Sulfo-GMBS as a cross-linker in PBS running buffer. Non-specific sites were
blocked with digested casein. TRIS was used to cap the cross-linker, blocking any
additional amines from covalently binding to the cross-linker on the chip surface. Ligands
were prepared as 20 mM stock solutions in dimethylsulfoxide (DMSO). Each ligand was
diluted to a final concentration of 500 µM in PBS just prior to injection (final DMSO
concentration was 2.5%). PBS and DMSO mixed in the same ratio were used as a blank.
Data collection and analysis were performed using the AnaLight Resolver.

A subset of the ligands identified to bind to CD81-LEL were also tested to
determine if they might block the HCV E2 protein from binding to CD81-LEL using DPI.
In these experiments, a recombinant form of the CD81-LEL protein was immobilized on
the chip and unreacted cross-linker was blocked as described above. Recombinant HCV
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E2 protein (Immune Technology Corp, New York, NY) was then injected to determine
the magnitude of the binding response when E2 bound to CD81-LEL in the absence of
the ligand. To evaluate the effect of a ligand on E2 binding to CD81-LEL, the same
experiment was repeated except that the E2 protein was premixed with the ligand at a final
ligand concentration of 500 µM. If the ligand inhibits E2 binding to CD81-LEL when the
mix of E2 and the ligand are added to the chip, the DPI binding response in the presence
of the ligand should be less than the response in the absence of the ligand. If a reduction
in E2 binding is observed by DPI, the magnitude of the inhibition can be calculated using
the binding responses for the ligand, the E2 protein and a mixture of the E2 protein and
the ligand.

3. Results and Discussion
3.1.

Target Regions on CD81-LEL

In this study we used the crystal structure of the open CD81-LEL conformation as
the target for the virtual screening runs performed using AutoDock to identify small
molecule ligands predicted to bind to cavities that encompass or are located near known
E2 contact residues. Based on mutation studies, Higginbottom et al. (17) identified four
residues that were considered to be essential for the HCV E2 protein to bind to CD81LEL. The Asp196Glu mutation in CD81 was observed to reduce binding to E2. In addition
mutations Phe186Leu and Glu188Lys inhibited binding of CD81 to E2, whereas the
Thr163Ala mutation enhanced their interaction (17). Drummer et al. (19) also examined
the binding site, which was estimated to cover approximately 806 Å2 of the CD81-LEL
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surface, and identified three additional amino acid contacts, Ile182, Asn184, and Leu162
(19) (figure 1). We used these seven residues as markers to identify the best regions on
the CD81-LEL protein surface to target when designing inhibitors to block the E2:CD81
interaction.

3.2.

The AutoLigand Fill Points and Energy Plot Analysis

AutoLigand was used to analyze the surface of CD81-LEL and select the best
ligand binding sites. Five binding sites were identified as potential targets by plotting the
total energy per volume (Kcal/mol ) for the fill points generated against the volume of the
filled site and picking those sites with the lowest values. Figure 2 shows the data from
each fill generated at different starting points on the surface using increasing numbers of
fill points to fill larger and larger volumes. The fill volumes with less than 100 Å3 are
small cavities within the protein structure that could be water or ion binding sites and were
not considered suitable drug targets. The open diamonds are the values for the fills near
amino acid Asn184, one of the five key residues shown previously to interact with E2.
The best fill for the site in this region, -0.165 Kcal/mol Å3, was obtained using 180 fill
points. As more points were used and the volume of the cavity increased, the predicted
free energy of binding became less favorable.

One site predicted by AutoLigand to be an excellent small molecule binding site
was located in a region that contained five of the CD81 amino acid residues (Ile182,
Phe186, Asn184, Glu188, Asp196) (19) that have been shown by others to interact with
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E2 (figure 3a). This is a large cavity located between the C and D helices that is only
present in the open conformation of CD81-LEL. A second group of fill points was
generated for a neighboring cavity located on the opposite side of the protein (figure 3b).
The fill points generated for these two sites were predicted to have the lowest interaction
energy of all the sites identified on the open conformation of CD81-LEL. Consequently,
these two sites were selected as the primary sites for use in small molecule docking.

3.3.

Docking and Analysis of Ligands Predicted to Bind to the Selected Sites

Docking runs were performed for the sites selected on CD81-LEL using the NCI
Diversity Set II, Sigma, and Asinex libraries of small molecules. The list of ligands
predicted to bind to each site were ranked according to binding energy and how well the
ligand’s atoms mapped onto the fill points for the site. In addition to the fill points defining
the rough shape of ligands that would fit best within the cavity, specific fill points were
also color coded to identify particular atoms (C,H,N,O) in the ligand that would interact
optimally with the surface of the protein in the regions surrounding the ligand (figure 4).
The fill points predicted for the site shown in Figure 4a are colored red for hydrogen
acceptors such as oxygen or nitrogen, blue for hydrogen, or grey for carbon. One of the
better ligands predicted to bind to this site (figure 4b) has atoms that superimpose well
with the fill point map (figure 4c). While the superimposition does not need to match
perfectly, the points of contact on the protein are considered to be good if the majority of
the different atom types in the molecule (75-80%) approximate the same location as the
fill points. Such ligands would be expected to form multiple contacts/interactions with the
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protein (such as hydrogen bonds, salt bridges, van der Waals interactions) and should bind
more tightly than other ligands predicted to make only one or two contacts.

3.4.

Experimental Confirmation of Ligand Binding

A total of 36 ligands were tested experimentally using surface Plasmon resonance
(Biacore T200 instrument) to identify which of the molecules predicted to bind to Sites 1
and 2 on CD81 actually bind to a recombinant form of the protein (CD81-LEL). Twentysix of the molecules provided a positive change in response units (RU) upon introduction
to a chip containing the immobilized protein (Table 1), indicating the ligands bound to the
protein. The measured responses for the ligands that bound varied from 2.3 to 78.4 RU.
Those ligands providing the largest responses tended to be molecules that were predicted
to bind more deeply inside cavities in Site 1 (ligands 30930, 98026, 7438, 5069) or Site 2
(ligands 78623, 127947, 16631, 38743). Control experiments were performed to confirm
that the recombinant form of CD81-LEL we used in these experiments had the correct
structure. In these experiments, the CD81-LEL protein was immobilized on a chip and
then DPI was used to show the HCV E2 protein recognized and bound to the immobilized
CD81-LEL (Table 2).

Six of the more interesting ligand candidates (three predicted to bind to Site 1 and
three predicted to bind to Site 2) were further tested to confirm they bind to CD81-LEL
using DPI. The results, shown in Figure 5, showed that all six ligands bound to the protein.
The relative rank in strength of binding of the Site 1 and 2 ligands, as determined by DPI,
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were also similar to the ranking obtained by SPR and the free energy of binding predicted
by AutoDock for the majority of the ligands. Ligands 1 - 4 exhibited binding responses
that were stronger than or equivalent to the binding observed for benzyl salicylate (0.58
radians, see Figure 5), a small molecule reported previously to block E2 binding to CD81
(33). Benzyl salicylate was identified by Holzer et al. (33) by performing a similar virtual
screen of small molecules (using a different set of databases) to the cleft we have referred
to as Site 1 in the open conformation of CD81-LEL. Thirty-seven analogs of benzyl
salicylate were subsequently synthesized by Holzer et al. (33) in an effort to enhance the
inhibitory activity of benzyl salicylate, but none of the analogs proved to be a better
inhibitor than parent compound benzyl salicylate.

For some ligands, significant differences were observed in the actual binding
responses obtained by SPR and DPI. As one example, Ligands 1, 2 and 5 had a very
similar binding response when tested by SPR, but these ligands exhibited different
responses when tested by DPI. One reason for this observed difference in the DPI response
might relate to conformational changes in the protein that occur when the small molecules
bind. The change in radians measured using DPI when a ligand binds to a protein is
known to result from a combination of two effects: 1) the resulting increase in mass and
volume when the ligand binds to the protein on the surface of the chip and 2) a
conformational change in the protein induced by the binding of the ligand. Small
molecules binding in deeper cavities would be expected to have more and stronger
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contacts with the protein than ligands sitting exposed to solvent in shallow cavities or
surface binding sites.

Those molecules predicted by AutoDock to have the lowest free energy of binding
also exhibited the largest DPI radians change and SPR response. The collective data
provided by the AutoDock free energy prediction, SPR, and DPI binding assays allowed
us to estimate and categorize the relative strength of the ligand’s binding to CD81-LEL
as strong, moderate or weak. Within the set of six ligands shown in Figure 5, Ligands 1,
2 and 4 exhibit the strongest binding, followed by ligands 5 and 6, which are categorized
as moderate binders. Ligand 3 appears to be the weakest binder in the group. Additional
SPR analyses performed using a series of Ligand 1 concentrations (figure 6) provided an
estimated Kd of 201µM for an affinity fit of Ligand 1 binding to the recombinant CD81LEL protein.

3.5.

Effect of Ligand 3 on in vitro Binding of HCV E2 Protein to CD81-LEL

Competition experiments were also performed to determine if selected Site 1 or
Site 2 ligands might block E2 binding to CD81-LEL. The two strongest binders in the Site
1 group shown in Figure 5 did not block E2 binding to CD81-LEL. Ligand 3 (689002),
on the other hand, was observed to reduce E2 binding to CD81-LEL by 40% (Table 2).
The magnitude of the reduction in the binding response in the presence of Ligand 3 is
consistent with Ligand 3 having an EC50 greater than 500 µM and being slightly less
effective than benzyl salicylate in inhibiting E2 binding to CD81-LEL. This result not
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only confirms that Ligand 3 binds within the E2 binding site on CD81-LEL, but it also
identifies a small molecule that could prove useful as an early stage drug lead in the
development of therapeutics that block HCV invasion.
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5. Figures

Figure 1. Amino acid residues that participate in HCV E2 binding to CD81-LEL The
colored residues are amino acids that have been identified by Higginbottom et al. (17) and
Drummer et al. (19) to contribute to the binding of the HCV protein E2 to CD81-LEL.
The structure shown is the monomer of the open conformation of CD81-LEL (PDB ID:
1G8Q). (a) Front view of the protein showing the four contact residues Leu162 (blue),
Ile182 (green), Asn184 (orange), and Phe186 (red). (b) Back side of the CD81-LEL
protein showing the other three contact residues Thr163 (yellow), Glu188 (cyan) and
Asp196 (magenta). This figure was prepared using AutoDock Tools version 1.5.6.
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Figure 2. Predicted free energy data for ligand binding sites identified on the surface
of CD81-LEL by AutoLigand. This figure was generated by plotting the total energy per
volume versus the volume of each fill made from different amounts of fill points. The
different symbols depict the fills that start in different locations within the five
cavities/sites identified by AutoLigand. Note that there are more than five sets of symbols
because some symbols represent fills starting in different locations within the same site
(e.g. the large cavity called Site 1). The most efficient fills are those that have the lowest
total energy per volume using the smallest volume. The fill points enclosed in the boxes
labelled Site 1 and Site 2 correspond to the fills used for docking. This figure was prepared
using AutoDock Tools version 1.5.6.
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Figure 3. Two ligand binding sites identified by AutoLigand on the open
conformation of CD81-LEL (PDB ID: 1G8Q) These two sites were selected as docking
targets based on their proximity to the amino acid residues that contact E2 (identified on
the molecular surface by blue, yellow, green, orange, cyan, red and magenta colors; see
Figure 1 legend for residue numbers) and the low free energy (high affinity) predicted for
ligands that would bind in this site. (a) The green spheres fill Site 1 and define its location,
the large cavity located between the C and D helices predicted by AutoLigand to be the
best binding site. Ligands binding to this site would bind very close to the majority of the
amino acids that participate in binding to E2. The green spheres correspond to the open
diamond fill points in Figure 2 located between 500 and 600 Å3. (b) The brown spheres
show the location of a second binding site, Site 2, predicted by AutoLigand on the
opposite side of the protein. Ligands binding to this site should also contribute to the
disruption of E2 binding. The brown spheres correspond to the black square fill points
shown in Figure 2 located between 550 and 650 Å3. This figure was prepared using
AutoDock Tools version 1.5.6.
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Figure 4. AutoLigand Analysis of the Site 1 ligand binding site AutoLigand fill points
not only identify cavities on the surfaces of proteins, but they also predict the structural
features of ligands that would bind with the best affinity and selectivity to the protein at
these sites. (a) The fill points provided by AutoLigand define the rough shape of ligands
that would fit best into the Site 1 cavity. Individual or groups of fill points are also color
coded (gray for carbon, light blue for hydrogen, and red for hydrogen acceptors oxygen
and nitrogen) to identify particular atoms in the ligand that would interact optimally with
the protein’s atoms or functional groups in the regions surrounding the ligand. (b) Ligand
1 is shown bound to Site 1 on CD81-LEL in the location and orientation predicted by
AutoDock. (c) The superposition of fill points (small spheres) provided by AutoLigand
and the actual atom types in Ligand 1 (large spheres) is high (75-80%) indicating that this
ligand should bind well in this particular site. Note that the amino acid residues that
contact E2 shown in Figure 1 are also shown in these figures using the same color-coding.
This figure was prepared using AutoDock Tools version 1.5.6.
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Figure 5. Confirmation of ligand binding to CD81-LEL using DPI Six of the ligands
that were found to bind to CD81-LEL by SPR analysis were selected and tested by a
second method, DPI, to confirm they bind to CD81-LEL. The results show that all six
ligands bind to the protein. The molecules are listed according to the assessed quality of
the ligand and its interaction with CD81-LEL using AutoDock’s predicted free energy of
binding and the DPI and SPR binding data. The relative rank in strength of binding of the
Site 1 and 2 ligands, as determined by DPI, were also similar to the ranking obtained by
SPR and the free energy of binding predicted by AutoDock. Ligands 1 - 4 exhibited
binding responses that were stronger than or similar to the binding observed for benzyl
salicylate, a small molecule reported previously to block E2 binding to CD81 (33).
Criteria used to define the quality of the ligands are: Strong - makes more than 5 contacts
with protein, predicted to be selective and not predicted to bind to multiple sites, not too
hydrophobic in addition to having an in silico binding energy of > -5, DPI binding of >
0.3 radians and SPR binding response of > 30 Response Units (RU); moderate - makes 45 contacts with protein, hydrophobic interactions contribute to binding in addition to
having an in silico binding energy of > -3, a DPI binding of > 0.15 radians and SPR
binding response of > 10; and weak – makes 3-4 contacts with protein in addition to
having an in silico binding energy of < - 3 , a DPI binding of <0.15 radians and SPR
binding response of < 10 RU.
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Figure 6. Binding of Ligand 1 to CD81-LEL as a function of ligand concentration
This binding experiment was performed using a Biacore T200 as described in the
Materials and Methods section. Using the data shown, Ligand 1 was estimated to have a
Kd of ~201µM based on an affinity fit.
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6. Tables
Table 1. Experimental analysis of ligand binding to recombinant CD81-LEL. Thirtysix ligands predicted by AutoDock to bind to Sites 1 and 2 on CD81-LEL were tested
experimentally using surface Plasmon resonance as described in the Materials and
Methods section. Ligand code numbers are those assigned by the National Cancer
Institute. The data, which are the response units generated by the Biacore instrument, are
shown for only the 26 ligands that were observed to bind. Because the binding
experiments were performed by passing the same concentration of each ligand
sequentially across the same protein coated chip, the magnitude of the response can be
used to provide an approximate ranking of binding strength. Response unit values greater
than 0 indicate binding.
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Table 2. DPI competition experiment showing inhibition of E2 binding to CD81-LEL
by Ligand 3 (689002) and comparing the inhibition to that achieved with benzyl
salicylate.
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CHAPTER IV
GENERATION OF A SHAL PROTOTYPE (SH7153) USING CD81-LEL AS A
TARGET
Objectives
The aim of this study is to generate a bidentate SHAL prototype (SH7153) and
test using Surface Plasmon resonance, antibody neutralizing assays and HCV infection
inhibition assays to determine its inhibitory effects on HCV. The computational biology
work was done at Scripps Research Institute (USA), Dr. Arthur Olson’s Molecular
Graphics Laboratory, the surface plasmon resonance binding assays were done at Caltech
(USA) at Dr. Jost Vielmetter’s protein expression center, and the HCV infections assays
were done at Institute Pasteur De Lille (France) at Dr. Jean Dubuisson’s lab.
1. Introduction
Several steps in the HCV life cycle are being actively targeted to create new drugs
that block virus invasion, processing of the pro-protein or replication of the viral genome
(1, 2). CD81 is considered a major HCV receptor that participates in the first step in the
process – entry of the virus into hepatocytes (3). A number of anti-CD81 antibodies have
been shown to block viral invasion and protect cells from the HCV cytopathic effect (4).
Holzer et al. was one of the first to select for and identify small molecules that target this
entry step (5,6). Two compounds identified in virtual and experimental screens performed
by this group, benzyl salicylate (5) and terfenadine (6), have been shown to be moderate
inhibitors of the HCV E2: CD81 interaction. we identified a second cavity within the E2
binding site adjacent to the large cleft targeted by Holzer et al. (5,6) using AutoLigand (7)
to search the surface of CD81-LEL near the amino acid residues in CD81 that participate
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in HCV envelope glycoprotein binding (8, 9). Virtual screening runs were performed
using AutoDock (10) to identify additional small molecules which might bind to the large
cavity targeted previously by Holzer et al. and to this new cavity, and 26 of those predicted
to bind were confirmed experimentally to bind to CD81. One of these ligands, 689002,
was also shown to block E2 binding (11). New experiments were conducted with the
ligands predicted to bind to the second cavity have identified another ligand that blocks
E2 binding to CD81-LEL. We have used these two ligands to design and synthesize a
prototype (first generation) selective high affinity ligand (SHAL) as a steric inhibitor to
block HCV E2 glycoprotein binding to CD81.
2. Materials and Methods
2.1.

Recombinant Proteins, Antibodies and Ligands
The recombinant HCV E2 glycoprotein was provided by Dr. Joseph Marcotrigiano

(Rutgers University-NJ/USA), His-CD81-LEL (Bioclone-CA/USA) , JS-81 antibody
(BD Pharmingen, 551108) and the small molecules were provided by the NIH/NCI
Developmental Therapeutics Program.

2.2.

Dual Polarization Interferometry
DPI analyses were performed using an AnaLight 4D workstation (Farfield Group,

Manchester UK). The recombinant CD81-LEL was immobilized onto a Thiol AnaChip
using Sulfo-GMBS as a cross-linker in PBS running buffer (pH 7.4). Non-specific sites
were blocked with digested casein. TRIS was used to cap the cross-linker, blocking any
additional amines from covalently binding to the cross-linker on the chip surface. Ligands
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were prepared as 20 mM stock solutions in dimethylsulfoxide (DMSO). Each ligand was
diluted to a final concentration of 500 uM in PBS just prior to injection (final DMSO
concentration was 2.5 %). PBS and DMSO mixed in the same ratio were used as a blank.
Data collection and analysis were performed using the AnaLight Resolver.
A subset of the ligands identified to bind to CD81-LEL was also tested to
determine if they might block the HCV E2 glycoprotein from binding to CD81-LEL using
DPI. In these experiments, a recombinant form of the CD81-LEL protein was immobilized
on the chip and unreacted cross-linker was blocked as described above. Recombinant
HCV E2 glycoprotein (Immune Technology Corp, New York, NY) was then injected to
determine the magnitude of the binding response when E2 bound to CD81-LEL in the
absence of the ligand. To evaluate the effect of a ligand on E2 binding to CD81-LEL, the
same experiment was repeated except that the E2 glycoprotein was premixed with the
ligand at a final ligand concentration of 500 uM. If the ligand inhibits E2 binding to CD81LEL when the mix of E2 and the ligand are added to the chip, the DPI binding response
in the presence of the ligand should be less than the response in the absence of the ligand.
If a reduction in E2 binding is observed by DPI, the magnitude of the inhibition can be
calculated using the binding responses for the ligand, the E2 glycoprotein and a mixture
of the E2 glycoprotein and the ligand.
2.3.

Surface Plasmon Resonance
SPR analysis was performed using a Biacore T100 workstation (GE Healthcare,

NJ, USA). A recombinant form of the CD81-LEL protein with a His-tag (BiocloneCA/USA) was used to determine the binding affinities of ligands 689002 and 93033 in
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addition to that of SH7153. Briefly, 10 uM CD81-LEL-His diluted into 10 mM sodium
acetate buffer pH 4.5 was immobilized for 15 min at a flow speed of 5 ul/min onto a CM5
sensor chip using amine coupling (EDC-NHS). Approximately 20,000 RU of protein were
immobilized on the chip. The ligands prepared as 200 uM solutions in PBS-1% DMSO
(the running buffer) and they were introduced to the protein using a pre-programmed 3
min association and 1 min dissociation interval. The binding affinities of selected ligands
were estimated using data collected from a series of SPR binding experiments conducted
at different ligand concentrations. To obtain the kinetic and affinity data needed to
estimate the Kd, the original ligand sample was diluted serially with running buffer to
produce five different ligand concentrations: 200, 66.6, 22.2, 7.41, 2.47 and 0 uM. Data
were fitted using a monovalent binding model.
2.4.

Solid phase synthesis of SH7153 and its analogues
Unless otherwise stated, all reagents and solvents were obtained from commercial

suppliers and used as received. 2Chlorotrityl chloride resin (100-200 mesh, 1% DVB, 1.2
mmol/g loading density) and all Fmoc-protected amino acids were obtained from
Novabiochem Inc. Fmoc-8-amino-3,6dioxactanonic acid (Fmoc-mini-PEG) was
purchased from Peptides Int. (Louisville, Kentucky- USA). The hexafluorophosphate
(PF6) salt of 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono-Nhydroxysuccinimide (DOTA-NHS) ester was purchased from Macrocyclics (Dallas,
Texas/ USA). N-(biotinyloxy)succinimide (biontinyl-OSu) was purchased from
BACHEM (Torrance, California/ USA). Dabsyl-L-valine (Dv acid) was purchased from
TCI Inc. (Tokyo).

( 3-(2-((3-Chloro-5trifluoromethyl)-2-pyridinyl)oxy)-anilino)-3-
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oxopropanionic

acid

(Ct

acid)

and

4-(4-(4chlorobenzyl)piperazino)-3-

nitrobenzenecarboxylic acid (Cb acid) ligands were procured from Bionet Research (Key
Organics Ltd. – Camelford, Pennsylvania/ USA)). Acetonitrile (MeCN), dichloromethane
(DCM), N,N-dimethylformamide (DMF), diisopropylethylamine (DIEA), hydrazine,
trifluoroacetic acid (TFA), 1,3-diisoproylcarbodiimide (DIC), 1-hydroxybenzotriazole
(HOBt), 20 % pyridine/DMF and triethylsilane (Et3SiH or TES) were purchased from
Sigma-Aldrich (St. Louis, Missouri / USA).

Instrumentation. Solid support syntheses were carried out in Pierce polyethylene
columns (5 mL). All SHALs were purified by semi-preparative HPLC at 10 mL/min on a
Waters preparative machine with photodiode array detection (Waters Symmetryprep C18,
7 µm, 19 x 300 mm column) and lyophilized using Kinetics Flexi-Dry freeze-dryer. The
purity was confirmed by analytical HPLC carried out at 1 mL/min on an Agilent 1100
machine (Waters Symmetry C18, 5 µm, 4.2 x 150 mm column, diode array detector) with
a linear gradient from 95 % H2O (1 % TFA) to 80 % MeCN (1 % TFA) over 12 min.
Mass spectra were acquired on a Micromass Quattro Micro API mass spectrometer
operating in positive ion mode. The samples were dissolved in MeCN / H2O (1:1), 0.1 %
formic acid for mass spectrometry analysis.
Preparation of Resin 1: 2-Chlorotrityl chloride resin (100 mg, 0.13 mmol) was
suspended in 2 mL dichloromethane (DCM) for 30 min and washed 3x with anhydrous
dimethylformamide (DMF). The resin was treated with Fmoc-D-Lys(Boc)-OH (20 mg,
43 µmol, 468.5 g/mol, 0.33 equiv. of the resin, the limiting reactant) and DIEA (25 µL,
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144 µmol) dissolved in 1.0 mL anhydrous DMF (Scheme 1). The reaction mixture was
agitated on a nutator for 3 h. Ethanol (1.0 mL) and DIEA (100 µL) was added and agitated
for 15 min to quench the excess chlorotrityl chlorides on the resin. The reaction solution
was removed by filtration and the resin was washed 3x with DMF and treated with 20 %
piperidine/DMF (1 mL) for 20 min for fluorenylmethoxycarbonyl (Fmoc) deprotection.
The Fmoc-deprotected resin-bound Boc-lysine (Resin 1) was washed with DMF and
subsequently coupled to the next Fmoc-protected residue using amide-coupling chemistry
employing ~4-5 molar equivalents of DIC and HOBt in DMF. The washing and filtration
cycle with DMF (2 mL, 3x, 1 min each) was performed between every deprotection and
coupling steps.
Preparation of Resin 2: Resin 1 was treated with a solution of Fmoc-8-amino3,6¬dioxactanonic acid (50 mg, 0.13 mmol, 385.4 g/mol, 3 equiv. of the limiting reactant),
DIC (30 µL, 0.19 mmol, 126.20 g/mol, 0.815 g/mL), and HOBt (26 mg, 0.19 mmol,
135.12 g/mol) in 1.0 mL anhydrous DMF for 3-5 h (coupling cycle 2, step 1a and 1b).
The resin was then treated with Fmoc-D-Lys(Dde)¬OH, HOBt and DIC in 1.0 mL
anhydrous DMF for 5 h (coupling cycle 3, step 2a and 2b). After Fmoc deprotection, the
resultant free amine was subsequently coupled to another solution of Fmoc-8-amino3,6¬dioxactanonic acid (Fmoc-mini-PEG), HOBt and DIC in 1.0 mL anhydrous DMF for
3-5 hours (coupling cycle 4, step 3a and 3b) producing Resin 2 after 20% piperidine/DMF
Fmoc deprotection and washing the resin with DMF to remove the excess reagents.
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Synthesis of SH7153. Resin 2 was treated with 93033 (32 mg, 0.085 mmol,
375.81 g/mol, 1.5 equiv.), HOBt and DIC in 1.0 mL anhydrous DMF for 5-12 h (coupling
cycle 8, step 1a). The reaction solution was filtered and the resin was washed and treated
twice with 4 % hydrazine in DMF (40 µL Hydrazine in 900 µL DMF for 10 min) to
remove the 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl (Dde) protecting group (step
1b). After washing, the resulting resin was treated with 689002 (30 mg, 0.080 mmol,
374.71 g/mol), HOBt and DIC in 1.0 mL anhydrous DMF for 5-12 h (coupling cycle 9,
step 2). In the last step, the solvent was exchanged from DMF to DCM (2 mL) and resin
was washed with DCM. The washed resin was then treated with 2 mL of 20 % TFA / 1 %
TES in DCM for 30 min to cleave the product from the resin as well as the Boc-protecting
group on the ε-amine of the first lysine residue. The cleaved solution was filtered and the
resin was washed with DCM. The combined DCM filtrate (red) was concentrated. The
crude material was analyzed by analytical Agilent HPLC (to determine the ratio of product
/ impurities in the cleaved material using UV absorbance peak areas at 254 nm).
Purification was performed using semi-preparative HPLC and the product fractions were
lyophilized to dryness. Analytical HPLC chromatograms and electron spray ionization
mass spectroscopy (ESI-MS) was used to confirm the final product.
2.5.

Antibody neutralizing assays
For antibody neutralization assay Raji cells were used, a human B cell line that

expressed high amounts of CD81 on the surface (data not shown). Cells were grown in
RPMI medium (10% FCS, 1% penicillin/streptomycin, 1% L-glutamine, 1% nonessential amino acids, 1% sodium pyruvate, pH 7.4, at 37oC with 5% CO2). 2x105 cells
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were incubated with or without different concentrations (50 µM, 100 µM, 400 µM and 1
mM) of indicated inhibitor for 20 min at room temperature, subsequently 1 ul (16 ng/µl)
of FITC-labeled anti CD81 antibody (BD Pharmingen, 551108) was added to the cells
and incubated for 20 min (antibody titration was performed to obtain a working dilution
range, data not shown). Cells were washed and analyzed by FACS (BD FACSCalibur,
software: Cell Quest Pro). Mean Fluorescence Intensity MFI was calculated using Flowjo
software (TreesStar, www.flowjo.com).
2.6.

HCV infection assays
Pseudotyped retroviral particles harboring HCV envelope proteins (HCVpp) from

different genotypes were produced as described previously [23, 24] with plasmids kindly
provided by F.L. Cosset, J. Ball, and R. Bartenschlager. A plasmid encoding the feline
endogenous virus RD114 glycoprotein [25] was used for the production of RD114pp.
Both HCVpp and RD114pp expressed Firefly luciferase.
The cell culture-produced HCV particles (HCVcc) used in this study were based
on the JFH1 strain [26] and were prepared as described previously [27, 28]. They were
engineered to express the A4 epitope, titer-enhancing mutations and Gaussia luciferase
[27,28].
To identify ligands that inhibit HCV infection, Huh-7 cells were seeded in 96-well
plates and treated the day after with six different concentrations of each ligand diluted in
DMSO in duplicate using a Zephyr automated liquid handling workstation (Caliper
BioSciences, Hopkinton, MA). The final concentration of DMSO (1%) was adjusted to
be the same for all ligand concentrations. Cells treated with DMSO were used as negative
controls. Cells treated with different concentrations of anti-CD81 (JS-81 from BD
Pharmingen, San Jose, CA) 1 hour before infection, were also used as positive controls.
The third day, RD114pp, HCVpp or HCVcc were inoculated and incubated for 30 hours
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at 37°C. Firefly and Gaussia luciferase assays were performed as indicated by the
manufacturer (Promega, San Luis Obispo, CA).
3. Results
Our previous analyses of two sets of small molecules predicted to bind to the large
cleft on the open conformation of CD81-LEL and to an adjacent cavity nearby identified
26 small molecules that bind to the large extracellular loop of CD81. These compounds
are being evaluated as potential leads for modification or optimization (e.g. by fragment
based drug design or the development of SHALs) to create steric inhibitors that block the
binding of HCV E2 glycoprotein to CD81 on hepatocytes. Using dual polarization
interferometry, one of these compounds (689002) was shown to block the recombinant
E2 glycoprotein binding to CD81-LEL immobilized on a chip. Additional binding studies
have been conducted in an effort to identify other ligands that might also block the HCV
E2: CD81 interaction and be used in combination with 689002 to create a bidentate SHAL
with improved CD81 binding.
3.1.

Identification of a Second Ligand that Blocks E2 binding to Recombinant
CD81-LEL
Dual polarization interferometry (DPI) experiments conducted with a set of small

molecules that were predicted to bind to a second cavity on CD81-LEL (11) (adjacent to
key CD81 amino acids (8,9) that contribute to CD81’s binding to the HCV E2
glycoprotein) identified a second small molecule that blocks recombinant E2 binding to
CD81-LEL. In these experiments, recombinant HCV E2 glycoprotein was immobilized
on a chip and dual polarization interferometry (DPI) was used to compare the binding of
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CD81-LEL, in the absence and presence of 500µM ligand, to the immobilized E2. As we
reported previously (11), the compound 689002 (9-Oxo-9H-thioxanthene-3-carboxamide
10,10-dioxide) was observed to block CD81 binding to E2 (Table 1). During the screening
of the Site 2 ligands, a second compound, 93033 (4-(2-(2,4-dioxo-1,2,3,4tetrahydropyrimidin-1-yl)acetamido)-2-hydroxybenzoic acid), was also found to block
CD81-LEL binding to E2. In both cases, the DPI response in radians produced by CD81LEL binding to E2 was reduced dramatically when the CD81-LEL-ligand mix was added
to the E2 immobilized on the chip. In contrast, ligand 30930 (5-(benzyloxy)-1H-indole2-carboxylic acid, which is shown as an example of a negative control) was observed to
have no effect on CD81-LEL binding.
3.2.

Design and Synthesis of a Prototype Bidentate SHAL
The lowest energy conformations of 689002 and 93033 bound to CD81-LEL, as

identified by AutoDock (figure 1A), were used to design a first generation bidentate
SHAL. As a first step, the distance from the amino nitrogen on 689002 and the carbon on
93033’s carboxyl group was measured to define a minimum length that would be required
for the linker connecting the two ligands. While the linear distance between these atoms
was measured to be 8.15A (figure 1B), the linker was designed to be longer (~12A) to
allow it to extend over the amino acid Glu188 (colored cyan) located between the two
ligand binding sites. Using this length to define the distance of separation between the two
ligands in the SHAL, a scaffold to which the two ligands would be conjugated was
designed (figure 2). As is typical of all first generation SHALs, lysine and miniPEG
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molecules were used to create the scaffold. Lysine residues were used at the terminus of
the SHAL to provide a free amine and free carboxyl group to which various tags and
effectors can be attached to the SHAL. Internal lysine residues were employed to provide
branch points within the scaffold. MiniPEG molecules were incorporated to provide
distance between linked ligands and also to make the linker flexible and contribute to
overall SHAL solubility.
Solid phase synthesis and carbodiimide coupling chemistry was used to connect
the components to the resin and create the molecular scaffold of the SHAL, and ligands
689002 and 93033 were subsequently conjugated to the appropriate sites on the scaffold
(figure 3). Following cleavage from the resin and HPLC purification, 20 milligrams of
SH7153 (molecular mass of 977.00 Da) were obtained. Two additional by-products of the
reaction, SH7153A (8 mg, molecular mass of 960.04 Da) and SH7153B (7 mg, molecular
mass of 993.97 Da) were also obtained (figure 4). SH7153A is a bidentate SHAL
containing two 689002 ligands linked together. SH7153B is a bidentate SHAL containing
two 93033 ligands linked together.
3.3.

Analysis of SH7153 Binding to CD81
SH7153 was first tested using surface Plasmon resonance to determine if it would

bind to recombinant CD81-LEL immobilized on a chip. As shown in Figure 5A, SH7153
not only bound to CD81-LEL, but it also dissociated slowly from the protein (koff ~ 2.17E04 1/sec). This is in marked contrast to the results obtained with the two ligands. Both
689002 and 93033 also showed reasonable binding responses, but the two ligands
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dissociate rapidly (figure 5B) as is characteristic of weakly bound small molecules. The
off rate for 689002 was 0.002631 1/sec and the off rate for 93033 was 0.00239 1/sec. A
series of binding curves were obtained for the SHAL and two ligands at different
concentrations to obtain an estimate of their affinities for recombinant CD81-LEL. Both
ligands bound weakly and had Kd’s that were greater than 200 µM (Table 2). SH7153, in
contrast, bound with a Kd of 21 µM.
The relative strength of binding of SH7153 and the two by-products of the SHAL
synthesis SH7153A and SH7153B to native CD81 was then tested by measuring their
ability to block the JS-81 antibody binding to Raji cells. It was shown that SH7153 and
the 2 by-products didn’t give a significant inhibitory effect.
4. Discussion and conclusions
Virtual screens performed in an earlier study by docking a large library of diverse
small molecules into two neighboring cavities on the open conformation of CD81-LEL
led to the identification of two sets of compounds that were predicted to bind to CD81
(11) in the same region where the HCV glycoprotein E2 has been reported to bind (8,9).
Experimental testing of these compounds revealed that 26 of the molecules bound to a
recombinant form of CD81 LEL. One of the molecules predicted to bind to the largest
cavity, 9-O-9H-thioxanthene-3-carboxamide 10,10-dioxide (689002), was found to block
E2 binding to recombinant CD81-LEL (11). Our recent testing of the other set of
molecules predicted to bind to the smaller cavity on CD81-LEL led to the identification
of a second compound that blocks E2 binding to CD81-LEL, 4-(2-(2,4-dioxo-1,2,3,4tetrahydropyrimidin-1-yl)acetamido)-2-hydroxybenzoic acid (ligand 93033).
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Both ligands 689002 and 93033 were identified by docking experiments
conducted using two cavities that are only present on the surface of the open conformation
of CD81-LEL (11). Although molecular dynamics studies of the open conformation
conducted by Neugebauer et al. (13) have been used to suggest that a second, closed
conformation of CD81-LEL reported by Kidadokoro et al. (14) was more likely to be the
physiologically relevant conformation, Neugebauer et al.’s (13) own analysis of the
dynamics data suggested the two conformations might exist in dynamic equilibrium. This
hypothesis has been supported by the small molecule binding studies we conducted using
recombinant CD81-LEL. More than 72% of the ligands predicted by docking to bind to
the large cleft/cavity present only in the open conformation of the protein were found by
experiment to bind to CD81-LEL (11).
The prediction that the two molecules bind to two adjacent cavities surrounding 5
of the 7 key CD81 amino acids that bind to E2, and the docked conformations of the two
molecules showing that both molecules contain carboxyl groups that do not appear to
interact appreciably with CD81 (so it is available for conjugation to a linker) and are
oriented toward each other all suggest 689002 and 93033 are good choices to link together
to create a prototype bidentate SHAL that targets the E2 binding site on CD81. The docked
conformations of the molecules bound to CD81-LEL were used to design a linker scaffold,
and the first CD81 SHAL, SH7153, was then synthesized using solid phase chemistry.
Upon purification by HPLC, SH7153 and two by-products (bidentate SHALs containing
two of the same ligands) were obtained.
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Surface Plasmon resonance analyses of SH7153 binding to CD81-LEL showed
the SHAL bound to the recombinant protein with a Kd of ~21µM. Estimates obtained for
the Kd’s of the two ligands used to create the SHAL (both 689002 and 93033 had Kd’s
>200 µM) indicate the linking together of 689002 and 93033 resulted in the production
of a SHAL with a Kd that is at least 10 fold higher than the Kd of the individual ligands.
In addition, the SHAL was observed to dissociate from CD81-LEL slowly with an offrate that is similar to or slower than the HCV E2 protein (15) and a number of HCV
neutralizing antibodies (16). Flow cytometry experiments were also conducted to examine
SH7153 binding to native CD81 on Raji cells using the JS-81 antibody as a competitor.
While an initial set of experiments suggested SH 7153 inhibited JS-81 binding to CD81
on Raji cells in a dose dependent manner, recent experiments have not confirmed that
inhibition. Subsequent HCV infection experiments also showed this first SHAL was not
effective in inhibiting HCV viral infection of Huh-7 cells.
While kinetic data obtained for a specific binding event that occurs between two
isolated proteins can contribute a great deal to our understanding of that particular
interaction, the results may not necessarily reflect what happens between the two proteins
in their native state. In the case of inhibitors designed to prevent HCV E2 binding to CD81
and block viral entry and cell infection, a number of factors can have a profound impact
on how well the drug induces its effect. Recombinant protein interactions in solution, for
example, may not be the same as the interactions that occur between E2 when it is
associated with the virus and CD81 when it is located in the target cell’s membrane. E2
is known to form a heterodimer with E1 in the membrane of HCV, and E2 in the dimer
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may react differently when E2 is free in solution. Protein structural dynamics may also
affect the number of available binding sites. The number of binding events required per
cell to trigger viral entry and infection, the number of available CD81 molecules, and
subtle structural variations in the HCV E2 protein expressed by different viral genotypes
that may modulate the interaction of the protein with CD81 are also important. The impact
of these factors may explain some of the variability in kinetic data others have obtained
and may have led to major differences in opinion as to what the Kd of an antibody or
inhibitor needs to be to effectively block HCV binding to CD81. Based on Kd’s
determined for HCV E2 binding to CD81, Petracca et al (17) suggested antibodies would
need to have nanomolar affinities to block HCV from binding to CD81. However, Keck
et al (18) and Nakajima et al. (15) reported Kd’s for HCV E2 protein binding to CD81
that were only in the micromolar range. The requirement for a Kd in the micromolar range
was further supported by the mathematical modeling of HCV viral kinetics conducted by
Padmanabhan and Dixit (19). The Kd for E2 binding to CD81 was estimated from their
mathematical treatment of HCV infections to be in the range of 10-100 µM.
The current results show that we can effectively combine rapid virtual screening
of large libraries of compounds with the experimental testing of a small number of hits to
identify lead small molecules that can be linked together to create a SHAL. By linking
together the two weak binding ligands 689002 and 93033, we have been able to create a
first generation bidentate SHAL that binds to CD81 with an affinity that is higher than the
affinities of the individual ligands used to create it. While this first SHAL did not inhibit
HCV infection of Huh-7 cells, the SHALs µM affinity and slow off-rate observed for the
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SHAL binding to CD81-LEL is encouraging. Based on our previous experience with
second generation SHALs developed for cancer therapy, improvements in binding affinity
and efficacy can be accomplished through the optimization of linker lengths, replacing
one ligand with another, or by adding a third ligand to create a tridentate SHAL.
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Figures. Figure 1. The binding modes of ligands 689002 and 93033 to CD81-LEL.
The docked conformations of ligands 689002 (pink) and 93033 (blue) are shown binding
to Sites 1 (large cleft on right) and Site 2 (smaller cavity on left) located within the E2
binding site on CD81-LEL (A). The linear distance between ligand carboxyl groups was
measured to be 8.15A, but linker was designed to be longer (~12A) to allow it to bend
over amino acid Glu188 (colored cyan) located between the two ligand binding sites (B).
6.

B

8.15Å
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Figure 2. The Linker Molecular Scaffold of SH7153. The molecular scaffold designed
to link ligands 689002 and 93033 together to create SHAL SH7153 is comprised on lysine
and miniPEG residues. The terminal lysine residue provide a free amine and carboxyl
group that can be used to attached tags or other effectors. Lysine residues are also
incorporated to provide branch points within the linker and miniPEG molecules are used
to provide distance between ligands and help optimize the SHAL’s solubility.
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Figure 3. Synthetic scheme used to synthesize SH7153. Solid phase synthesis was
performed on a chlorotrityl resin. For a detailed description of the synthesis, please see
the Experimental section

.
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Figure 4. Structures of the two SHAL by-products isolated from the SH7153
preparation by HPLC. SH7153A was found to contain two 689002 ligands linked
together. SH7153B was found to contain two 93033 ligands linked together.

SH7153A

SH7153B
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Figure 5A. Binding and dissociation curves for the SHAL SH7153 and its two ligand
components binding to recombinant CD81-LEL obtained by surface Plasmon
resonance. A detailed description of the experiment is described in the Experimental
section. A. Binding and dissociation of SH7153. B. Binding and dissociation of the ligand
component 93033.
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7. Tables
Table 1. DPI data for ligands 689002 and 93033. Ligands 93033 and 689002 were found
to interfere with HCV E2 binding to CD81.Ligand 30930 was used as a negative control.

Added to E2 on Chip

DPI Response in Radians (Rad)

CD81-LEL

2.52

30930

2.52

93033

0.25

689002

-0.23
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Table 2. The kinetics study of SH7153, ligands 689002 and 93033.
Ligand or SHAL

Kd (µM)

Off rate (1/sec)

93033

>200

0.00239

689002

>200

0.002631

SH7153

21

2.17E-04
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CHAPTER V
281816- A NOVEL DRUG LEAD IDENTIFIED TO INHIBIT HCV INFECTION
IN A GENOTYPE-INDEPENDENT MANNER
This chapter is based on a paper titled “Identification of a novel drug lead that inhibits
HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.” that
was submitted to Plos one by: Reem R. Al Olaby, Laurence Coquerel, Adam Zemla, Jean
Dubuisson, Laure Saas, Jost Vielmetter , Joseph Marcotrigiano, Abdul Ghafoor Khan,
Felipe Vences Catalan, Alexander L. Perryman, Joel S. Freundlich, Stefano Forli,
Shoshana Levy, Rod Balhorn , Hassan M.E. Azzazy.
Objectives
The aims of this study is to create a new homology model of HCV E2 based on
the newly resolved crystal structures (PDB IDs: 4MWF, 4NX3), screen ~2000 ligands
against the HCV E2 homology model and identifying top virtual screening hits, test the
hits using lab on a chip techniques and antibody neutralizing assays, test the ligands with
the best binding affinity using HCV infection inhibition assays and do further tests for the
drug lead 281816 to determine its effect on cell to cell transmission of HCV and other
aspects. The Homology model was created by Dr. Adam Zemla (Lawrence Livermore
National Laboratory – USA), the virtual screening runs were conducted in Scripps
Research Institute (USA), Dr. Arthur Olson’s molecular graphics laboratory and Rutgers
University (USA) at Dr. Joel Freundlich’s lab. The HCV infection inhibition assays were
done in Institute Pasteur De Lille (France) at Dr. Jean Dubuisson’s lab and the antibody
neutralizing assays were done in Stanford University (USA) at Dr. Shoshana Levy’s lab.
1. Introduction
Hepatitis C Virus (HCV) is a global public health problem [1] in which nearly
85% of affected individuals have acute HCV infections and exhibit no symptoms. In
addition, more than three-quarters of these cases will advance to chronic disease, which
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include liver cirrhosis and liver cancer [2]. The current standard of care treatment for HCV
(Peginterferon/Ribavirin, PR) can cause deleterious side effects, and a sustained virologic
response (SVR) is achieved in less than 50% of genotype-1 patients [3]. The FDA
approved protease inhibitors Telaprevir (TVR) and Boceprevir (BOC) have been shown
to provide higher SVR rates in genotype 1 patients [3, 4] when each is combined with PR.
However the poor safety profile of TVR and BOC reported in the Week 16 analysis of the
French Early Access Program suggest there is still a need for better HCV drugs [5]. The
two most recent FDA approvals have been for the oral drugs Simeprevir and Sofosbuvir,
inhibitors that target the HCV NS3/4A protease and polymerase, respectively [6].
Semiprevir, which needs to be administered with ribavirin and peg-interferon, has a
number of undesirable side effects [7]. The efficacy of Semiprevir has also been shown
to be diminished significantly due to viral breakthrough (HCV RNA rebounds and
becomes detectable in the patient before treatment is completed), in patients infected by
HCV genotypes 4-6 containing the Q80K, R155K and D168E/V polymorphisms [7].
Recommendations for the use of Sofosbuvir indicate it should be administered with
Ribavirin to HCV genotype 2 and 3 infections and that Peg-Interferon should be included
in the treatment when infections involve genotypes 1 and 4. While Sofosbuvir is
considered the Holy Grail in HCV treatment by some, it is recommended that treatments
be limited to 12 weeks [6]. Its high cost ($1,000 USD/pill) also puts it out of reach of
many HCV infected patients. This has led many of the larger pharmaceutical companies
to continue developing new drugs that target one or more steps in the HCV life cycle and
block virus invasion, processing of the pro-protein or replication of the viral genome.
Several research groups have shown that the CD81-large extracellular loop
(CD81-LEL) plays a key role in HCV entry into cells by binding to the HCV envelope
glycoprotein 2 (E2) [8-11]. Zhang et al. [12] elucidated a separate, additional function for
CD81 in the HCV life cycle. These studies revealed that CD81-LEL is important for
efficient HCV genome replication. In addition, the E2-CD81-LEL interaction has been
determined to induce several immuno-modulatory effects such as the production and
release of pro-inflammatory cytokine gamma interferon from T-cells. In addition, this
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interaction has also been shown to down regulate T-cell receptors and suppress the activity
of natural killer (NK) cells [13]. Therefore, it is tempting to speculate that blocking the
CD81- LEL:HCV E2 interaction might also contribute to arresting disease progression to
liver cirrhosis.
Following the discovery of the E2 glycoprotein’s role in HCV infection and
disease progression, several approaches have been used to attempt to develop anti-HCV
drugs and vaccines that target the HCV E2 glycoprotein [14-17]. These efforts have had
to deal with challenges that relate to the genomic diversity and heterogeneity of HCV,
limitations in animal models used to test vaccines and drugs, and the lack of a resolved
crystal structure for the HCV E2 glycoprotein. Recently, two crystal structures have been
reported for the core ectodomain of the HCV E2 protein [18, 19]. Kong et al. [18] obtained
the structure of amino acid residues 384-746 (E2c) by designing and expressing 41 soluble
HCV E2 constructs and selecting 15 to screen against E2-specific Fab fragments in
crystallization trials. Using a combination of x-ray crystallography and negative stainelectron microscopy, Kong et al. [18] showed that the structures they obtained for E2 were
globular and very different from the predicted models of E2 that were developed using
class II fusion protein templates containing three β-sheet domains. Additionally, they were
able to identify key CD81-binding residues through mutational studies. Important CD81
binding sites were determined to be in the epitope recognized by the neutralizing antibody
AR3C, along one s

-sandwich (an isolated region of the CD81-binding loop)

and a front layer consisting of loops, short helices and β-sheets [18-20]. AR3C was also
found to cross-neutralize HCV genotypes by blocking CD81 binding to HCV E2 [21].
During the preparation of this manuscript, a second structure was reported for E2c (amino
acid residues 492-649) by Khan et al. [19]. This new structure, which was obtained by
crystallizing E2c in complex with a FAB fragment of the mouse monoclonal antibody
2A12, is highly similar to the previously reported structure. In addition to providing a
second structure for the E2 core from a different HCV genotype (2a), new information
was also reported on the accessibility of the E2 core amino acids within the structure using
a combination of limited proteolytic degradation and deuterium exchange.
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Despite the advances in the field of HCV drug development, the current drugs
offer little protection against the emergence of genetic variants (escape variants) of HCV
– a feature of HCV biology that complicates both drug and vaccine development. Drugs
that target only one step in the HCV life cycle may be less effective in treating patients
who become infected with these emerging variants. In an effort to develop a suitable drug
candidate that targets the majority of the existing HCV genotypes, we developed an HCV
E2 homology model based on the new HCV E2 core crystal structure reported by Kong
et al. [18] and have used this model to identify small molecule drug leads that target highly
conserved sites on the HCV E2 glycoprotein located within the region bound by CD81.
AutoDock was used to perform virtual screening runs against 1715 small molecules and
34 of the best compounds were tested experimentally using surface Plasmon resonance
(Biacore T100) to identify a set of small molecules that bind to the recombinant E2
protein. The compounds showing binding activity were then tested for their ability to
block HCV infection of Huh-7 cells. One compound, 281816, was found to block
infection of the cells by each of the HCV genotypes and subtypes tested (1a, 1b, 2a, 2b,
4a and 6a) in a dose-dependent manner. Experiments with Huh-7 cells have shown that
both mechanisms that lead to HCV infection, cell-free and cell-to-cell transmission, are
abrogated by 281816. Inhibition of cell-free infection is limited to the viral attachment
step, as well as interactions occurring during viral internalization and fusion; 281816
appears to have no effect on post-entry processes.
2. Results
a. Structural model of E2
In order to maximize the likelihood that these experiments would lead to the
discovery of small molecules that bind to E2 and block E2’s binding to CD81, we
developed a homology model of the core of the E2 protein containing the domains known
to bind to CD81 to use as our docking target. This model was created using the HCV
genotype 1a protein sequence NP_751921.1 and the crystal structure of E2c as the primary
template (PDB entry: 4MWF) (18). Using a model, rather than the E2c crystal structure,
was important because the reported structure of E2c was determined to be unsuitable for
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the docking experiments we needed to perform. The atom coordinates listed in PDB
chains 4mwf_C and 4mwf_D provide structural information for only 169 and 171 residues
respectively out of the 363 amino acids present in the full-length E2 protein. Within each
of deposited PDB chains three stretches of amino acid sequence (large loop P453-P491
containing 39 amino acids, T542-G547 or V574-N577, and F586-R596) are missing in
the crystal structure (figure 1A). Unfortunately, similar regions are also missing in the
crystal structure of the genotype 2a HCV E2c protein (PDB chain: 4nx3_D) reported by
Khan et al. [19] which provides atom coordinates for only 119 amino acids. Structural
superposition of 4mwf_C and 4nx3_D (figure 1B) shows strong conformational
similarities between the experimentally solved structures of the E2 proteins with a root
mean square deviation of 1.07 Ångstroms measured on 98 residues for which distances
between corresponding Cα atoms are under 3 Ångstroms. The most significant structural
deviations are observed in the region 566-601 (numbering from 4mwf_C) which
corresponds to the region that also exhibits the greatest variation in sequence (see
sequence alignment in Figure 1A).
Exhaustive structure similarity searches of 90 residue structural fragments of E2
conducted using the entire PDB database (255,302 PDB chains) revealed that no
additional structural homologs could be found at the level of calculated structure
similarities by LGA score [22] higher than LGA_S=45%, suggesting that the HCV E2
protein represents a novel fold in the current PDB. Thus, the modeling of the structure of
the insertions needed to fill in missing regions in the experimentally solved crystal
structure and to complete the model was a difficult task, and it was completed with a very
low degree of confidence. By applying a combination of structural modeling and analysis
methods to the E2 crystal structure (see Materials and Methods section), we were able to
construct a model that met all the requirements needed for docking. This model contains
the peptide segments and loops that are missing in the E2c structure (figure 2), the missing
fragment with amino acids known to be critical for E2 binding (W487), as well as the
exact sequence for the HCV genotype 1a E2 protein. Three regions that have been
identified by others to be critical for E2 binding to CD81 [24-26] are contained in the
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model in their entirety (figure 2). Currently, however, only three of the twenty-one Region
1 amino acids (H421-N423) are present in the model. A comparison of our model to the
two E2c structures (see bar plots in the Figure 1A and superposition of two structures in
Figure 2) shows the main core regions are, as one would expect, very similar. The
differences that are observed in the core region are small and appear to reflect only minor
local deviations between experimentally solved structural templates. The large region that
does differ corresponds to the missing peptide segments (Figure 4).
b. Ligands predicted to bind to CD81 binding sites on E2
Five ligand-binding sites on the HCV E2 homology model (Figure 3) were
identified by docking of the National Cancer Institute’s Diversity Set III library of ligands
to the E2 model. Each of these sites is associated with or positioned next to one or more
of the amino acid or peptide sequences that have been identified by others to either
participate in E2 binding to CD81, E2 binding to E1 or to be important for HCV
infectivity. The first sequence of importance is the peptide segment Q412-N423 that was
identified to bind to the broadly neutralizing antibody AP33 [20, 27]. Alanine mutagenesis
studies have shown all of the amino acids in this region appear to be important for HCV
infectivity [24]. The model used in this study currently contains only three of the amino
acids that correspond to this segment, H421, I422 and N423. Sequence 2 spans the second
hyper-variable domain of E2, extending from amino acid Y474 to R492 [13, 24-26]. The
majority of amino acids in this sequence have been shown to have no effect on E2 binding
to CD81 when mutated [23], but antibodies binding to this region of the protein do inhibit
HCV infectivity [25] and CD81 binding [27]. One amino acid located within this domain,
W487, does however appear to be critical for E2 binding to E1. This amino acid is the
first residue in one of the WHY motifs that have been reported to play a role in E1:E2
dimerization [26]. The third sequence spans amino acids S522–G551 [20,24-26] and the
fourth sequence of importance is comprised of amino acids P612–P619 [25]. Mutations
of residues Y527, W529, D535, Y613, R614, W616, H617 and Y618 in these two regions
have all been shown to eliminate E2 binding to CD81 [23,25]. Mutating all but three of
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these amino acids (D535, R614 and W616) appears to eliminate specific interactions with
CD81. W616 is the first amino acid in another WHY motif that is located in a region
(G600-C620) that has been shown to be involved in fusion [28]. Alanine mutagenesis of
D535, R614 and W616 was found to disrupt the structure of the AR3A epitope and
indirectly impact CD81 binding [25].
These five binding sites were used to guide to our selection of the top virtual
screening hits to be tested experimentally for binding to recombinant E2 protein. While
there is still some debate regarding the importance of the entire domains bound by
neutralizing antibodies, amino acid mutagenesis studies have provided a great deal of
insight into those amino acids located within the epitopes that participate in E2 binding to
CD81. Based on this information, we have used the set of amino acids W420-I422, S424,
G523, Y527, W529, G530, D535, P612-R614 and W616-P619, whose mutation has been
shown to eliminate E2 binding to CD81, to identify locations within these sites (figure 3)
where ligand binding would be expected to disrupt E2’s ability to bind to CD81.
Thirty-four of the highest scoring ligands were selected from the docking run for
experimental analysis. Conformers of each of the ligands bound to one or more of these
five binding sites. The best ligands were considered to be those that exhibited the lowest
free energy of binding and were predicted to interact with or bind nearby one or more of
the E2 amino acids within the sites that were reported to be critical for E2 binding to
CD81. The free energy of binding predicted for the best bound ligand conformations,
shown in Table 1, ranged from -6.2 to -8.7 Kcal/mol. Additional criteria used to select
among the group of ligands predicted to bind include the number of contact
points/interactions (such as hydrogen bonds, salt bridges, Van Der Waals interactions)
with amino acids in the model (the larger number of contacts or interactions the better)
and the chemical structure of the ligands (preference is given to those that contain a free
amino or carboxyl group that is exposed to solvent). Ligands with free amino or carboxyl
groups can easily be linked to other ligands to create higher affinity or more selective
second-generation inhibitors.
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c. Experimental confirmation of ligand binding to HCV E2
Each of the 34 ligands was tested experimentally using surface Plasmon resonance
detection (on a Biacore T100 instrument) to determine if it would bind to recombinant
HCV E2 protein and to obtain an assessment (relative to the other ligands) of how well it
binds. Twenty-three of the molecules provided a positive change in response units (RU)
indicating they bound to the E2 protein immobilized on the chip (Table 2). The measured
responses for the ligands that bound varied from 54 to 276 RUs. Data was also obtained
on the rate of ligand dissociation by measuring the amount of ligand remaining bound at
two time points, dissociation 1 (10 seconds) and dissociation 2 (50 seconds), during the
rinsing of the chip with buffer (figure 5). The majority of the ligands dissociated quickly,
as one might expect for small molecules that bind to the surface of a protein. A few, such
as ligands 121861, 4429, 158413, 81462, and 57103, exhibited slower off rates when
compared to others.
d. Inhibition of HCV Entry
The 23 compounds that were observed to bind to recombinant E2 protein were
then tested to determine if they would block HCV infection of Huh-7 cells. Pseudotyped
retroviral particles harboring the envelope protein of an endogenous feline retrovirus
(RD114pp) were first used to determine the specificity and the safety of molecules. We
excluded from a further characterization the molecules for which the half maximal
inhibitory concentration (IC50) against RD114pp was higher than 10 µM or the molecules
that significantly increased RD114pp infection due to exerting non-specific inhibition
(Table 3). The remaining ligands were next tested against pseudotyped retroviral particles
harboring genotype-2a HCV envelope proteins (HCVpp 2a), cell culture produced HCV
particles (HCVcc) or RD114pp. As a positive control, an anti-CD81 antibody was
included in the assays. One compound, 281816, showed an inhibitory effect on both
HCVpp and HCVcc infection with IC50’s of 1.02 µM and 3.95 µM, respectively (Table
3 and Figure 6A), indicating that this molecule inhibits the entry step of the HCV lifecycle,
probably through a specific effect on the virus’s interaction with CD81. While Huh-7 cell
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toxicity was not observed over the range of ligand 281816 concentrations tested in the
assays (the highest concentration tested was 10µM), a subsequent viability assay (MTS
assay) showed a 50% cytotoxic concentration (CC50) for 281816 of 14 µM (data not
shown). MTS is a tetrazolium compound that can be reduced by viable cells to generate
formazan products that are directly soluble in cell culture medium.
To determine if 281816 would inhibit HCV genotypes other than 2a, a series of
infection assays was performed with HCVpp bearing envelope proteins from a number of
different HCV genotypes. Interestingly, 281816 was found to be equally effective in
inhibiting Huh-7 infection by all the HCV genotypes tested (1a, 1b, 2a, 2b, 4a and 6a,
Figure 6B). The IC50 values ranged from 2.2 µM to 4.6 µM (Table 4).
To confirm that 281816 inhibits HCV entry with no further effect on post-entry
steps, 281816 (10 µM) was added at different time points (figure 8A) before (-2 to 0 hr,
b), during (0 to 2hr, c), or after (2 to 24hr, d) inoculation of Huh-7 cells with HCVcc, as
previously described [29]. Cells treated with dimethylsulfoxide (DMSO) and cells treated
continuously (-2 to 24hr, a) with 281816 were used as controls. The results clearly showed
that 281816 significantly inhibits HCVcc infection when present during virus infection
(figure 8A, c). The decrease in HCVcc infection that was observed in condition b is likely
to be due to some 281816 entering into the cells and acting on the entry step (figure 8A,
b). Similarly, a slight decrease was also observed in condition d (figure 8A), which is
likely related to 281816 acting on the entry of the remaining particles (those entering after
2 hr). Together, these results confirm that 281816 inhibits the entry step of HCV lifecycle.
After attachment to the cell surface and binding to entry factors, HCV virions are
internalized by clathrin-mediated endocytosis [30, 31]. Following internalization, HCV is
transported to early endosomes along actin stress fibers, where fusion seems to take place
[31, 32]. To determine at which step HCV entry is impaired by 281816, we administered
the ligand at different intervals during the early phase of infection. Virus attachment and
binding were performed at 4°C (figure 8B, Steps 1 and 2). Then, cells were shifted to
37°C to allow endocytosis and fusion (figure 8B, Step 3). Cells treated with JS81 were
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used as controls where JS81 antibody binds to CD81 and blocks HCV E2: CD81
interaction (data not shown). The addition of 281816 during step 2 and step 3 led to the
strongest inhibition of HCV infection, as strong as the one observed when 281816 was
present during all three steps. We also observed a significant inhibition of HCV infection
when 281816 was added during the early attachment/binding steps (figure 8B, Step 1).
Together, these results indicate that 281816 inhibits HCV infection by acting on more
than the first (attachment/binding) step of viral entry. These data suggest the ligand also
affects interactions during HCV internalization and fusion.
e. Blocking of E2 binding to CD81
Ligand 281816 was originally selected for testing based on the prediction by
docking that it would bind to a site on the HCV E2 protein where CD81 binds. The
infection assay conducted with Huh-7 cells demonstrated 281816 was effective in
inhibiting the entry step in the HCV life cycle. To confirm that the binding of 281816 to
E2 inhibits the HCV E2-CD81 interaction, flow cytometry was used to monitor the
binding of a recombinant form of the E2 protein to native CD81 overexpressed on Raji
cells as a function of 281816 concentration. The results in Figure 7 show binding of the
E2 protein to Raji cells is inhibited by 281816 in a dose dependent manner.
f. 281816 abrogates HCV cell-to-cell transmission
In addition to cell-free infection, HCV can also be transmitted via cell-to-cell
contact by a mechanism that is not completely understood [33, 34, 35]. Indeed, HCV is
transmitted in the presence of monoclonal antibodies (mAbs) or patient-derived
antibodies that are able to neutralize virus-free infectivity [33,35]. Since cell-to-cell
transmission has been suggested to be a major route of transmission for HCV [34], we
next analyzed the effect of 281816 on this process. For this purpose, Huh-7 cells were
infected with HCVcc for 2h and then cultured with neutralizing anti-E2 antibody (3/11)
in the presence of 281816 (1 µM and 10 µM). Cells cultured in presence of solvent
(DMSO) and Epigallocatechin-3-gallate (EGCG, 50 µM) [35] were used as negative and
positive controls of inhibition, respectively. Three days post-infection, foci were
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visualized by immunofluorescence (figure 9) and sizes of foci were measured by counting
the number of cells per focus. The results showed that 281816 led to a significant
reduction of the number of cells per focus in a dose-dependent manner. Together, these
results indicate that 281816 also inhibits cell-to-cell transmission of HCV.
3. Discussion
While it has been known for some time that the E2 envelope glycoprotein plays
an important role in the life cycle of HCV, we are only now beginning to learn details
about the structure of the protein and how it functions. This has been attributed to the
challenging intrinsic properties of the protein, such as the presence of multiple flexible
loops, its tendency to form disulfide aggregates in solution and the high level of N-linked
glycosylation, all of which make it difficult to determine the protein’s structure.
Neutralizing antibody epitope analyses and mutation studies, however, have provided a
great deal of information about the regions of the E2 protein and specific amino acids that
participate in CD81 binding and are important for HCV infectivity.
It became possible to use computational docking and structure-based drug design
methods to begin developing anti-HCV drugs that target the conserved regions of E2 and
block its interaction with host receptors due to two reasons. First, the recent determination
of two HCV E2 protein core crystal structures [18,19]. Second, our use of the deposited
coordinates to create a new homology model of the protein’s structure containing the
majority of conserved segments known to be important for viral invasion of hepatocytes.
Our docking of a library of diverse small molecules to this homology model led to the
identification of a set of ligands that were predicted to bind to sites near key amino acids
known to participate in CD81 or E1 binding or block HCV infection, and 23 of the 34
compounds were confirmed by experiment to bind to recombinant E2 protein.
When these 23 ligands were tested for activity in blocking HCV infection of Huh7 cells, only ligand 281816 was found to inhibit HCV infection using both HCVcc and
HCVpp based assays. Upon analyzing the activity spectrum of HCV using HCVpp
bearing envelope proteins from different HCV genotypes (1a, 1b, 2a, 2b, 4a and 6a),
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281816 was found to inhibit the infection of all tested genotypes with IC50’s ranging from
2.2 µM to 4.6 µM (Table 4), indicating that this small molecule inhibits HCV entry in a
genotype-independent manner. Ligand 281816 was also observed to block the binding of
recombinant E2 protein to Raji cells expressing CD81.
The docking experiments conducted with 281816 identified the two different
binding sites on E2 shown in Figure 10. One cluster of 281816 conformers bound deep
inside a cavity positioned directly above Y618 and P619, two amino acids in site 4 that
are known to contribute to E2’s binding to CD81 [26]. The two strongest 281816 ligand
binding modes are shown bound to this site. 281816 was also predicted to bind to a
shallow cavity on the side of the protein. These conformers were predicted to bind to site
1 near residues V515, G517, P515 and H421-N423. H421-N423 is part of a larger segment
of E2 that has been shown to bind to CD81 [19]. As expected, the ligand positioned above
Y618 and P619 in the deeper cavity was predicted to bind more strongly to the protein
(free energy of binding of the best bound ligand = -8.64 Kcal/mol) than when it was bound
to the shallow cavity on the side of the protein (free energy of binding = -6.39 Kcal/mol).
A subset of the 281816 conformers (not shown) in the cluster observed to bind
near site 4 overlapped into site 2 and bound immediately adjacent to D481-P490, part of
the epitope targeted by antibodies that block HCV infectivity and E2 binding to CD81
[27]. W487, a residue within this peptide segment whose mutation has been shown to
disrupt E2:E1 dimerization [22], is also located near site 2. Other conformers in the cluster
binding on the side of the protein also bound near site 5 and amino acid residues P612 and
Y613. One interesting and unique feature of the 281816 ligand is that a number of its
conformers are predicted to bind immediately above or next to the exposed faces of the
P612-P619 domain that is known to participate in E2 binding to CD81 [26]. The limited
proteolysis and deuterium exchange experiments conducted with the E2 protein core and
reported by Khan et al. [19] indicate these 281816 binding sites are accessible and exposed
to solvent.
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To probe more deeply into the inhibition of the infection process by 281816,
experiments were also run to determine if the inhibition of cell-free infection by 281816
might be limited to viral entry, which step in the entry process might be affected by the
compound, and what impact, if any, 281816 might have on cell-to-cell transmission of
HCV. Analyses of Huh-7 cells inoculated with HCVcc before, during or after treatment
with 281816 revealed the compound only blocks HCV entry and does not inhibit postentry processes in the HCV life cycle. A kinetic analysis of the effect of 281816, coupled
with a temperature block to endocytosis and fusion, was used to examine the cell-free
entry steps in more detail and showed 281816 inhibits not only the initial
attachment/binding step, but it also has an effect on interactions that occur later during
viral internalization and fusion. Ligand 281816 was also observed to abrogate the cell-tocell transmission of HCV. 281816 treatment of Huh-7 cells cultured in the presence of the
anti-E2 neutralizing antibody 3/11 not only led to a dose dependent reduction in the
number of cells forming foci, but it was found to be more effective in blocking cell-tocell transmission that the Epigallocatechin-3-gallate [35] used as a positive control.
In addition to identifying a promising new small molecule drug lead for treating
HCV that targets the E2 glycoprotein, this study also provides a demonstration of the
utility of our new E2 homology model in the discovery of small molecules that bind to
important sites on E2. By targeting sites containing amino acid residues identified by
others to participate in CD81 binding and CD81-dependent processes that impact HCV
infectivity, a small molecule was identified that not only blocks E2 binding to CD81 and
the cell-free entry process, but it is also effective in blocking the cell-to-cell transmission
of HCV – the predominant mechanism of transmission that contributes to the persistence
of infections [34]. This effect of 281816 corroborates other reports of a CD81-dependent
cell-to-cell transmission process [61.61] that can be blocked by anti-CD81 antibodies
[34,66] and soluble CD81 [32]. 281816, known as methiothepin or 1-methyl-4-(3methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazine, is also interesting
because it has been determined previously to block dopamine [36] and serotonin [37]
receptors and has been shown to inhibit a number of other biological activities, which
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include the binding or entry of two other unrelated viruses into cells (Lassa [38], Marburg
[39]), Plasmodium falciparum proliferation [40], and Mycoplasmodium tuberculosis
infections [41].
4. Materials and Methods
a. Creation of the homology model of E2 used for docking
A crystal structure of E2c deposited in the PDB under a code 4MWF was resolved
by Kong et al. [18] at a resolution of 2.65 Angstroms. However, upon examination of the
structure file prior to docking, the set of reported atom coordinates of the protein was
found to be incomplete. In addition to the coordinate file containing structural information
for only 171 residues out of the 363 amino acids present in the full-length protein,
structural information was missing for several peptide segments or loops within the
structural core of the protein. In order to prepare a more complete version of the structure
for docking, we have performed several homology modeling and structure analysis tasks
using the coordinates of E2c as a template. The final structural model was created using
the AS2TS system [42] based on atom coordinates from the PDB chains 4mwf_C and
4mwf_D. A structural search for similar fragments in proteins in the PDB that could be
used to model missing loop regions was performed using the StralSV algorithm [43],
which identifies protein structures that exhibit structural similarities despite low primary
amino acid sequence similarity. The side-chain prediction was accomplished using
SCWRL [44] when residue-residue correspondences did not match. Residues that were
identical in the template and E2 protein were copied from the template onto the model.
Potential steric clashes were identified in the unrefined model using a contact-dot
algorithm in the MolProbity software package [45], and the constructed model was
finished with relaxation using UCSF Chimera [46].
b. Virtual screen of the NCI Diversity Set III to the HCV E2 protein model
AutoDock VINA 1.1.2 (VINA) [47] was used to perform a virtual screen of the
NCI Diversity Set III against the homology model that was created using the new crystal
structure developed by Kong et al. [18] (PDB ID: 4MWF) as a template. The model of
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the protein was prepared for docking using the MolProbity Server (to add all of the
hydrogen atoms and to flip the HIS/ASN/GLN residues if doing so significantly lowered
the energy) and AutoDockTools 4.2 (which added the Gasteiger-Marsili charges and
merged the non-polar hydrogens onto their respective heavy atoms) [48,49]. The NCI
Diversity Set III library containing 1,715 models of compounds was obtained from the
ZINC server (http://zinc.docking.org) [50]. The multi-molecule “mol2” files from ZINC
were prepared for docking calculations using Raccoon [51], which added the GasteigerMarsili charges, merged the non-polar hydrogen atoms onto their respective heavy atoms,
and determined which bonds should be allowed to freely rotate during the calculations, to
generate the “pdbqt” docking input format.
Four different, overlapping grid boxes were used in this virtual screen to enable
the docking calculations to explore almost the entire surface of this E2 model (except for
the large, flexible loop that was added to the model and the relatively flat surface near
it). Since large grid boxes were used in these calculations, the “exhaustiveness” setting
in VINA was increased to 20. Each calculation used 8 CPUs on the Linux cluster at
Rutgers University-NJMS. The first box, which included P490, was centered at 38.829,
12.968, -40.958 (x, y, z) and had the following dimensions: 24.0 x 35.0 x 30.0 (x, y, z in
Angstroms). The second grid box, which included G436, was centered at 48.401, 11.791,
-14.449 (x, y, z) and had a size of: 32.0 x 36.0 x 24.0 (x, y, z in Angstroms). The third
grid box, which included S528, was centered at 51.644, 25.877, -27.795 (x, y, z) and
encompassed 30.0 x 30.0 x 30.0 Angstroms. The fourth grid box, which was selected to
include the side of E2 not covered by the previous three grid boxes, was centered at
57.777, 12.968, -34.067 (x, y, z) and enclosed 24.0 x 35.0 x 32.0 Angstroms (x, y, z).
The docking outputs generated by VINA were processed and filtered using python
scripts from Raccoon2 and Fox [51]. The top-ranked VINA mode from each docking
calculation was harvested, and 17 different sets of energetic and interaction-based filters
were investigated to harvest the most promising docking results for visual
inspection. The following parameters were explored in the filtering process: -e indicates
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the minimum estimated Free Energy of Binding from the VINA score in kcal/mol, -l is
the minimum ligand efficiency value in kcal/mol/heavy atom, -S is the minimum number
of hydrogen bonds between the ligand and target, and -H indicates that the ligand had to
form a hydrogen bond with either a backbone amino group (::N) or a backbone carbonyl
oxygen (::O) of any residue in that grid box.
For the results with grid box 1, filters 12 and 13 each harvested 70 and 51
compounds, respectively. Those filtered sets were pooled together to form a set of 96
unique compounds for visual inspection. Filters 14 (which harvested 11 compounds), 15
(which harvested 21 compounds), and 1 (which harvested 34 compounds) were pooled
together from the results with grid box 2, in order to identify 52 compounds for visual
inspection. Similarly, for the results with grid box 3, filters 1 (which harvested 25
compounds), 14 (which identified 20 candidates), and 15 (which harvested 13
compounds) were pooled to obtain 34 compounds for visual inspection. To identify
candidates in the results with grid box 4, filters 1 (which harvested 26 compounds), 14
(which harvested 19 compounds), and 15 (which harvested 14 compounds) were pooled
to obtain 42 compounds. These four different pools of potentially promising compounds
were then visually inspected to select the ligands to be tested experimentally for binding
to recombinant E2 protein.
c. Expression and purification of the HCV E2 protein Con1eE2
A construct containing a sequence encoding amino acids 384-656 of the Con1
envelope protein 2 ectodomain (eE2) [19], a genotype 1 E2 sequence, was cloned into a
lentiviral expression vector containing a carboxy-terminal Protein A tag separated by a
PreScission Protease cleavage consensus sequence. eE2-ProtA was stably expressed in
HEK293T cells using lentiviral infection. The protein was secreted into the media and
supernatants were purified using IgG Sepharose (GE Healthcare, Piscataway, NJ). eE2ProtA was eluted with 100 mM sodium citrate and 20 mM KCl at pH 3 directly into tubes
containing 1M Tris pH 9 for immediate neutralization. PreScission Protease (GE
Healthcare, Piscataway, NJ) was added to the eluted sample at a ratio of 1:50
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(enzyme:eE2), and the digest was then dialyzed into 20 mM HEPES pH 7.5, 250 mM
NaCl, 5% glycerol. eE2 was separated from the cleaved tag and the PreScission Protease
by ion exchange chromatography [19].
d. Experimental analysis of ligand binding to recombinant E2 by surface
Plasmon resonance (SPR) detection
A set of 34 of the ligands predicted by AutoDock to bind to E2 were tested
experimentally to determine if they bound to recombinant E2 protein immobilized on a
chip using surface Plasmon resonance detection. The SPR analyses were performed using
a Biacore T100 workstation (GE Healthcare, NJ, USA) and recombinant HCV E2 protein.
1 µM HCV E2 was diluted into 10 mM sodium acetate buffer pH 5 and immobilized for
15 min at a flow speed of 5 µl/min onto a CM5 sensor chip using amine coupling (EDCNHS). Approximately 10,000 response units (RU) of protein were immobilized on the
chip. His-CD81-LEL (Bioclone Inc, San Diego, CA) binding to HCV E2 was tested as a
positive control prior to injecting the ligands to confirm the E2 protein was functional and
would bind CD81-LEL. In a typical experiment with CD81, 1µl of his-CD81 (50nM) in
114 µl PBS was injected into channel 2 and 106.4 RUs of CD81 bound to the E2 on the
chip. This was followed by testing the binding of the 34 virtual screening hits where the
ligands were prepared as 200 µM solutions in PBS and they were introduced to the protein
using a pre-programmed 3 min association and 1 min dissociation interval. The response
was measured at two time points during dissociation, 10 and 50 seconds, to obtain
information on the rate of ligand dissociation from E2.
e. HCV infection assays
Pseudotyped retroviral particles harboring HCV envelope proteins (HCVpp) from
different genotypes were produced as described previously [52, 53] with plasmids kindly
provided by F.L. Cosset, J. Ball, and R. Bartenschlager. A plasmid encoding the feline
endogenous virus RD114 glycoprotein [54] was used for the production of RD114pp.
Both HCVpp and RD114pp expressed Firefly luciferase.
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The cell culture-produced HCV particles (HCVcc) used in this study were based
on the JFH1 strain [55] and were prepared as described previously [56, 57]. They were
engineered to express the A4 epitope, titer-enhancing mutations and Gaussia luciferase
[56,57].
To identify ligands that inhibit HCV infection, Huh-7 cells were seeded in 96-well
plates and treated the day after with six different concentrations of each ligand diluted in
DMSO in duplicate using a Zephyr automated liquid handling workstation (Caliper
BioSciences, Hopkinton, MA). The final concentration of DMSO (1%) was adjusted to
be the same for all ligand concentrations. Cells treated with DMSO were used as negative
controls. Cells treated with different concentrations of anti-CD81 (JS-81 from BD
Pharmingen, San Jose, CA) 1 hour before infection, were also used as positive controls.
The third day, RD114pp, HCVpp or HCVcc were inoculated and incubated for 30 hours
at 37°C. Firefly and Gaussia luciferase assays were performed as indicated by the
manufacturer (Promega, San Luis Obispo, CA).
The analysis of the effect of 281816 ligand on Huh-7 infection by HCVpp bearing
envelope proteins from different genotypes was performed in 24-well plates using the
method described above. This ligand was also screened for toxicity to the cells using the
MTS

(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-

2Htetrazolium) assay [58].
f. Inhibition of Recombinant E2 binding to native CD81
The human B cell line Raji (ATCC, Manassas, VA), which expresses high levels
of CD81 on its surface, was used to determine if ligands inhibit the binding of HCV-E2
protein to native CD81. Purified HCV-E2 protein (4 µg) was pre-incubated with 1,5,15,
50, 100 or 400 µM of the ligand 281816 for 25 min at RT. After pre-incubation the E2ligand complex was added to the cells and incubated for 25 min. The complexes were
washed from the cells and 0.5 µg of anti E2 antibody (clone H53) was added followed by
secondary anti mouse-FITC (Southern Biotechnology, Birmingham, AL). The cells were
washed, fixed with 3% paraformaldehyde, and analyzed by flow cytometry (BD FACS
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Calibur, software: Cell Quest Pro) analysis. The mean fluorescence intensity (MFI) was
calculated using Flowjo software (TreesStar, www.flowjo.com).
g. Antibodies
Mouse anti-E1 A4 [59] and rat anti-E2 3/11 [60] were produced in vitro using a
MiniPerm apparatus (Heraeus Instruments - Germany). Alexa555-conjugated goat antimouse immunoglobulins were obtained from Jackson Immunoresearch (West Grove, PA).
JS-81 (PharMingen, Oxford, England) was used according to the manufacturers’
protocols.
h. HCVcc cell-to-cell transmission assay
Huh-7 cells were seeded on coverslips and infected with HCVcc for 2h at 37°C.
Cells were then washed and cultured for 72h at 37°C in culture medium containing
neutralizing anti-E2 antibody (3/11 mAb ; 50ug/ml) in presence of 281816 at the
indicated concentrations. Cells cultured in presence of DMSO and Epigallocatechin-3gallate (EGCG, 50 µM) [35] were used as negative and positive controls of inhibition,
respectively. Cells were fixed with formalin solution (formaldehyde 4%, Sigma, St Louis,
MO), and foci detected by indirect immunofluorescence using the anti-E1 monoclonal
antibody A4.
i. Kinetics of entry
Cells treated with 281816 at 10µM or with DMSO were infected with HCVcc for
1h at 4°C (attachment/binding period). Virus was removed, cells were washed with
medium and incubated again for 1h at 4°C (post-attachment/binding period). Cells were
then washed and incubated for 1h at 37°C (endocytosis/fusion period). Lastly, cells were
washed and incubated in complete culture medium for 21h. Infection levels were
monitored by measuring luciferase activities.
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6. Tables
Table 1. Ligands predicted to bind to the HCV E2 protein by blind docking of the NCI
Diversity set III small molecule library to the HCV E2 structural model.
Ligand
ID

670283
86467
639174
81462
403379
213700
359472
146554
204232
281816
308835
60785
84100
158413
57103
121861
3076

Free
Energy of
Binding
(Kcal/mol)
-7.69
-7.47
-7.81
-6.81
-7.58
-7.89
-7.91
-7.67
-8.54
-8.64
-8.4
-7.48
-6.99
-7.9
-6.36
-8.16
-7.71

Ligand
ID

211490
113486
144694
4429
133071
163910
54709
135618
281254
319990
369070
59620
38968
171303
228155
13316
117268

Free
Energy of
Binding
(Kcal/mol)
-8.7
-6.26
-7.27
-7.3
-7.5
-7.4
-7.3
-8.7
-6.5
-7.4
-6.3
-7.3
-3.9
-5.8
-8.7
-6.8
-7.6
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Table 2. Magnitude of surface Plasmon resonance binding response obtained for the 23
ligands that were identified to bind to recombinant E2 protein immobilized on a CM5
sensor chip. The rate of ligand dissociation is assessed by measuring the response units at
two time points (10 sec and 50 sec) after the chip with bound ligand is rinsed with buffer.
Ligand
ID
670283
86467
639174
81462
403379
213700
359472
146554
204232
281816
308835
60785
84100
158413
57103
121861
117268
3076
211490
113486
144694
4429
133071

Binding
(RU)
54.3
54.9
55.4
57.2
58
62
62
63.4
63.4
64.5
64.8
70.4
71.2
71.2
81.6
88.4
88.5
92.2
102.9
104.7
118.8
155.3
276.3

Dissociatio
n 1 (RU)
4
1.9
2.3
9.2
2.8
3.1
2.5
3.1
2.5
3.7
7.1
2.8
4.2
10.3
11.4
26.1
4.1
3.2
6.1
7
6
28.9
1.8

Dissociatio
n 2 (RU)
1.4
0.8
0.6
6.5
1.1
0.8
0.8
0.8
0.4
0.9
5.2
0.6
2.2
8.5
2.5
20.4
1.2
1.6
2.1
2.6
2.3
14.2
-2
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Table 3. The IC50 values obtained for the 23 ligands screened for their ability to inhibit
HCVcc, HCVpp and RD114pp infection of Huh-7 cells. ND refers to molecules for which
the half maximal inhibitory concentration (IC50) against RD114pp was higher than 10
µM or the molecules that significantly increased RD114pp infection.
Ligand
ID

IC50 (µM)
RD114
pp

HCVpp

HCVcc

670283
86467
639174
81462
403379
213700
359472
146554
204232
281816
308835
60785
84100
158413
57103
121861
117268
3076
211490
113486
144694
4429
133071
AntiCD81

3
>10
0.03
>10
>10
>10
>10
>10
>10
>10
>10
3.5
>10
>10
0.3
>10
0.1
0.25
0.5
>10
>10
>10
0.10
>10

ND
>10
ND
>10
>10
>10
>10
ND
>10
1.02
>10
ND
>10
>10
ND
>10
>10
ND
ND
>10
>10
>10
ND
0.17

ND
>10
ND
>10
>10
>10
>10
ND
>10
3.95
>10
ND
>10
>10
ND
>10
>10
ND
ND
>10
>10
>10
ND
0.36
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Table 4. Genotype independent inhibition of HCVpp infection of Huh-7 cells by ligand
281816.

Subtypes
HCVpp 1a
HCVpp 1b
HCVpp 2a
HCVpp 2b
HCVpp 4a
HCVpp 6a

IC50 (µM)
2.95
4.66
2.22
2.93
3.44
3.30
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Figures
Figure 1. Comparison of structural templates used for modeling of HCV E2c protein.
(A) Bar representation of structural similarities between crystal structures 4MWF chains
C and D, and 4NX3 chain D. Regions reported in coordinates span amino acid residues
from H421 to N645. In the column Seq_ID are provided sequence identities between
amino acid sequences taken from coordinates and corresponding sequence fragments
from HCV E2 protein of genotype 1a. In GREEN are colored regions where structural
deviations are below 3 Ångstroms measured as Cα-Cα distances between corresponding
residues from the superimposed structures. In RED are regions where structural data is
missing or deviations are greater than 3 Ångstroms. (B) Structural superposition of
4mwf_C and 4nx3_D shows strong conformational similarities between experimentally
solved structures of E2 proteins for which the level of sequence identity is 69%. In blue
and purple are colored structural fragments where two structures 4mwf_C (566-601;
BLUE: light-dark) and 4nx3_D (568-605; PURPLE: light-dark) significantly differ.

(A)

133

(B)
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Figure 2. Comparison of the crystal structure of E2c with the homology model.
Structural superposition between E2c crystal structure from the PDB chain 4mwf_D (red)
and the homology model (black) is illustrated using ribbons representation. It shows
overlap in structure conformations in most of the regions, except the fragments where
coordinates in the experimental structure are missing (red dashed lines).
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Figure 3. . Location of five ligand binding sites used to select ligands for experimental
testing. Each of these sites either covers or is located immediately adjacent to amino acids
or peptide segments of the E2 protein known to be important for HCV infectivity. H421N423 (yellow): each amino acid in this region important for infectivity. Amino acids
Y474-R492 (light cyan) have been shown to prevent infectivity, but this region of the
protein has no effect on E2 binding CD81. W487 (dark cyan) is a key amino acid that is
involved in E2 binding to E1. S522-G551 (light green) and Y527 and W529 (dark green)
are critical for E2 binding to CD81. Site 4: P612, Y613, and H617-P619 (red) are critical
for E2 binding to CD81; mutations to R614-W616 (pink) disrupts the structure of the
region.
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Figure 4. Comparison of the crystal structure of E2c with the homology model. A.
E2c crystal structure (red). B. Homology model (black). C. Superposition of the two
structures. The residues colored red remain unchanged from the crystal structure. The
residues colored black show the structure is either different or not present in the crystal
structure.
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Figure 5. Surface Plasmon resonance sensogram (Biacore T100). This figure shows
sensorgrams (binding and dissociation plots) for two of the ligands that bound to the
recombinant E2 protein immobilized on a CM5 chip, 86467 (green) and 121861 (red),
and the 3 reference points that are used to measure the binding and dissociation
(dissociation 1 and dissociation 2) of the compound expressed in response units (RU).
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Figure 6. 281816 inhibits HCV entry in a genotype-independent manner. (A) Huh-7
cells in 96-well plates were pre-treated with 281816 (left and middle panels) or anti-CD81
antibody (right panel) at the indicated concentrations and then infected with HCVpp 2a
or HCVcc. (B) Huh-7 cells in 24-well plates were pre-treated with 281816 at the indicated
concentrations and infected with HCVpp expressing envelope proteins from the indicated
genotype. After 30 hours of infection, cells were lysed and luciferase activity quantified.
HCVpp infections were normalized to RD114pp infections.
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Figure 7. 281816 inhibition of HCV E2 protein binding to CD81 on Raji cells. Flow
cytometry was used to quantify recombinant HCV E2 protein binding to native CD81
over-expressed on Raji cells. Binding of the recombinant E2 protein to native CD81 on
the surface of Raji cells was detected using the mouse monoclonal E2 antibody clone H53
followed by staining with a secondary anti mouse-FITC antibody as described in the
Materials and Methods section. E2 binding is inhibited by 281816 in a dose-dependent
manner up to 100µM.
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Figure 8. 281816 inhibits HCV entry. A, Huh-7 cells in 24-well plates were treated at
different time points with 281816 at 10µM and infected with HCVcc for 2h at 37°C.
281816 was added full-time during the experiment (a), 2h before virus inoculation (b), 2h
during virus inoculation (c), or full-time after virus inoculation (d). B, Huh-7 cells were
infected with HCVcc for 1h at 4°C (Step 1: attachment/binding), then virus was removed
and cells incubated again at 4°C for 1h (Step 2: post-attachment/binding). Finally, cells
were shifted at 37°C for 1h (Step 3: endocytosis/fusion) and left at 37°C for 21h. 281816
was added at 10µM either during the Step 1, Step 2, Step 3 or Steps 1-2-3. * and *** mean
p values below 0.05 and 0.0001, respectively.
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Figure 9. 281816 blocks HCV cell-to-cell transmission. Huh-7 cells were seeded on
coverslips and infected with HCVcc for 2h at 37°C. Cells were then washed and cultured
for 72h at
presence or in absence of 281816 at indicated concentrations. Cells cultured in presence
was determined by A4 indirect immunofluorescence. ** and *** mean p values below
0.001 and 0.0001.
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Figure 10. 281816 binding sites on HCV E2. 281816 (structure, top) is predicted to bind
to two sites on the E2 protein. Different conformers of 281816 are shown bound in the
two sites. The E2 amino acids are color coded as described in Figure 2.
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CHAPTER VI
IN SILICO DESIGN OF SHAL PROTOTYPE (SH2216) AGAINST HCV USING
HCV E2 AS A TARGET PROTEIN
Objective
Designing a bidentate SHAL prototype by selecting 2 potential ligands to be incorporated
into the SHAL and measuring the distance between their free carboxyl and aminogroups.

1. Introduction
HCV E2 is considered one of the significant viral proteins that are involved in the
internalization of HCV into hepatocytes through its interactions with several host proteins
(1-4). The newly resolved crystal structure of the core of HCV E2 made it easier to
develop a homology model for the whole or most of the E2 protein (figure 1) (5,6). This
in turn helps in targeting the model by doing virtual screening runs, analyzing the results
and determining top virtual screening hits. Upon validating true binders using surface
Plasmon resonance, those are further tested using infection inhibition assays so as to see
which has an inhibitory effect on HCV.
The previous chapter discussed how 281816 was identified to be a genotypeindependent inhibitor in a dose dependent manner. It was also found that 281816 binds to
several potential binding sites on the E2 model in silico. These results have suggested we
try to design an in silico bidentate SHAL (SH2216) which is formed of a pair of 281816
ligand analogue.
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2. Materials and methods
2.1.
Creation of the homology model of E2 used for docking
Two crystal structures of E2c have recently been deposited in the PDB under codes
4MWF and 4NX3 were resolved by Kong et al. (5) at a resolution of 2.65 Angstroms and
Khan et al. (6) at a resolution of 2.4Å. However, upon examination of the structure prior
to docking, both sets of reported atom coordinates of the protein were found to be
incomplete. In addition to the coordinate file containing structural information for only
171 residues out of the 363 amino acids present in the full-length protein structure
obtained by Kong et al. (5), structural information was missing for several peptide
segments or loops within the structure. Several peptide segments were also missing from
the Khan et al. (6) structure file. In order to prepare a more complete version of the
structure for docking, we have performed several homology modeling and structure
analysis tasks using the coordinates of Kong et al.’s (5) E2c as a template. The final
structural model was created using the AS2TS system (7) based on atom coordinates from
the PDB chains 4mwf_C and 4mwf_D. A structural search for similar fragments in
proteins in the PDB that could be used to model missing loop regions was performed using
the StralSV algorithm (8), which identifies protein structures that exhibit structural
similarities despite low primary amino acid sequence similarity. The side-chain prediction
was accomplished using SCWRL (9) when residue-residue correspondences did not
match. Residues that were identical in the template and E2 protein were copied from the
template onto the model. Potential steric clashes were identified in the unrefined model
using a contact-dot algorithm in the MolProbity software package (10), and the
constructed model was finished with relaxation using UCSF Chimera (11).
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2.2.

281816 Docking to HCV E2 homology model
AutoDock 4.2 (12,13) was used to perform 281816 docking to HCV E2 model.

The parameters were set at 100 for the number of genetic algorithm (GA) runs, 150 as the
population size, and a maximum number of generations of 25000. The Lamarckian genetic
algorithm in AutoDock was used to perform the docking experiment. Docking results
were sorted to identify the binding sites that 281816 binds to and the different between
free binding energies.
2.3.

Determining an analogue for 281816 and docking it to HCV E2 homology
model
One of 281816 Analogues (Ligand 22594527) was chosen to design an in silico

prototype of SHAL. It was docked to the HCV E2 homology model, and the binding mode
was analyzed. The binding sites were determined and 2 were chosen. The distance
between the 2 sites were measured and the number of mini-PEG moieties to be used was
determined. Avogadro was used to link the 2 281816 ligands with mini-PEG and Lysine
to create a bi-dentate SHAL (SH2216).
3. Results and Discussion
Ligand 281816 was predicted to bind to two different sites on E2 shown in Figure
2. One site is located deep inside a cavity positioned directly above Y618 and P619, two
amino acids known to contribute to E2’s binding to CD81. The second site was located in
a cavity on the opposite of the protein. In this second site, the ligand is positioned directly
above residues R614-W616 and immediately adjacent to P612 and Y613 and H421-N423.
These amino acid residues comprise Sites 1 and 4 and the residues in both sites are amino
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acids that have been shown to be critical for E2 binding to CD81. As expected, the ligand
positioned above Y618 and P619 in the deeper cavity was predicted to bind more strongly
to the protein (free energy of the best bound ligand = -8,64 Kcal/mol) than when it was
bound to the more shallow cavity on the other side of the protein (free energy = -6.39
Kcal/mol). One interesting and unique feature of the 281816 ligand is that it is predicted
to bind to both of the exposed faces of the 612-619 domain that is known to participate in
E2 binding to CD81.
Owing to the fact that 281816 doesn’t have neither a free amino group nor a free
carboxyl group, a search for an analogue that has either of these groups was necessary.
Ligand 22594527 was one of the analogues that were found to be suitable for a SHAL
synthesis (figure 3). This ligand was docked to HCV E2 model and was found to bind in
the first site to PRO619 and TRP616 (figure 4a), and in the second site to PRO612 and
TYR613 (figure 4b) which makes it having similar binding mode to 281816. These 2
binding sites were chosen depending on the binding modes of Ligand 22594527 and the
significant residues that were previously determined to be involved in HCV E2: CD81LEL interaction. This was followed by measuring the distance between the 2 sites (figure
4c) which was found to be in the range between 26-27.5 A and determining the number
of mini-PEG and lysine residues that are needed to link the two molecules together in such
a manner that one ligand can bind to each site simultaneously.
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5. Figures
Figure 1. The four binding sites selected to guide the virtual screening runs on HCV
E2 homology model. Site 1: Yellow (412-423) each amino acid in this region important
for infectivity. Site 2 Light cyan (474-492) prevents infectivity, no effect on E2 binding
CD81; Dark cyan 487 (involved in E2 binding to E1). Site 3 Light green (522-551); Dark
green 527, 529 (critical for E2 binding to CD81). Site 4: Red (612, 613, 617-619, critical
for E2 binding to CD81); Pink (614-616) disrupts structure of region.
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Figure 2. 281816 binding sites on HCV E2. 281816 binds three sites. Clusters of
different conformations of bound 281816 molecules are shown bound in the three sites.
Sites and amino acids are color coded as described in Figure 2.
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Figure 3. The structure of 281816 analogue. 281816 analogue (22594527)- Z)-but-2enedioic
acid;N'-(3-methylsulfanyl-5,6-dihydrobenzo(b)(1)benzothiepin-5-yl)ethane1,2-diamine.
CSC1=CC2=C(C=C1)SC3=CC=CC=C3CC2NCCN.C(=CC(=O)O)C(=O)O
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Figure 4. The 2 chosen binding sites that ligand 22594527 binds to. The first site
comprises residues PRO619 and TRP616 (a) and the second site compromises PRO612
and TYR613 (b). The distance between the free aminogroup of the first ligand binding to
site (a) and that binding to site (b) was found to be in the range 26-27.5 A (c).

A

Front

B
Side
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C

26.210
7.721
20.55
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Figure 5. Bidentate SHAL from 2 ligands 22594527. The distance between the 2 ligands
binding on the same site is around 10.22 A. Which enables generating a bidentate (b) and
tridentate (c) SHAL without the use of linkers.

C(CC(=O)NCCNC2C3=C(SC1=CC=CC=C1C2)C=CC(=C3)SC)(C@@H)(C(=O)NCCNC
5CC4=CC=CC=C4SC6=C5C=C(C=C6)SC)NC(C(CCCCN)N)=O

B
A

C

C(CC(=O)NC(C(=O)NCCNC2CC1=CC=CC=C1SC3=C2C=C(C=C3)SC)CCC(=O)NCCNC5CC4=CC=CC=
C4SC6=C5C=C(C=C6)SC)(C@@H)(C(=O)NCCNC8CC7=CC=CC=C7SC9=C8C=C(C=C9)SC)NC(C(CC
CCN)N)=O
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CHAPTER VII
IDENTIFICATION OF DRUG LEADS THAT BLOCK PLASMODIUM
SPOROZOITES: CD81-LARGE EXTRACELLULAR LOOP INTERACTION
Objectives
The aim of this study is to screen ~2000 ligands against the residues in CD81-LEL
that are involved in CD81: Plasmodium sporozoites interaction, test the hits using lab on
a chip techniques and antibody neutralizing assays followed by testing the ligands with
the best binding affinity using Sporozoite Invasion assays. The Sporozoite invasion assays
were conducted in John Hopkins University (USA) at Dr. Photini Sinnis’s lab.

1. Introduction

Malaria is caused by protozoan parasites belonging to the genus Plasmodium.
Malaria in human is caused by four types which are: Plasmodium malariae, Plasmodium
ovale, Plasmodium vivax and Plasmodium falciparum. P. falciparum and P. vivax are the
two major species involved in global malaria (1). Malaria infection starts by the invasion
of the parasite into the hepatocytes (Liver stage) followed by blood stage.

In order for Plasmodium species to propagate in the host and establish an infection,
they should be internalized into the hepatocytes (2). The mechanism of interaction of
plasmodium sporozoites with hepatocytes is still not clear however, hCD81 was found to
be one of the significant surface proteins on the hepatocytes required by the sporozoites
to invade the liver cells (3-5).
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CD81 belongs to tetraspanin family. It possesses ubiquitous functions such as cell
adhesion, migration, cell fusion, co-stimulation, signal transduction, and differentiation
(Reviewed in 6). It was found that antibodies to CD81 or CD81 silencing largely inhibits
the infection of hepatocytes by Plasmodium falciparum sporozoites. Additionally, it was
found that Plasmodium yoelii sporozoites do not have the ability to infect CD81-deficient
mouse hepatocytes both in vitro and in vivo (3-5).
Yalaoui et al. (7) identified specific amino acid residues in CD81 that are
important for infection through conducting mutational studies. They found a stretch of 21
amino

acid

residues

that

are

required

for

invasion

(135-

VVDDDANNAKAVVKTFHETLD-155) (figure 1) (7).
In our study we targeted those amino acid residues by creating 3 grid parameter
files (figure 2), used them to guide the virtual screening runs against ~ 4000 ligands,
analyzed 500 of the resulting docked ligands, determined the virtual screening hits and
tested the hits in vitro using surface Plasmon resonance and antibody neutralizing assays
to validate binding to CD81 and inhibition of CD81: antibody interaction.
2. Materials and Methods
2.1.

In silico Experiments
In this study we used three different grid boxes (3 regions) to encapsulate the

region of CD81 that has the amino acid residues involved in malaria infection of liver
cells. A total of ~4000 ligands from the NCI Library were docked against each of these
grid boxes in the crystal structure of hCD81 (PDB ID: 1G8Q). This was followed by
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analyzing the results (filtering, visually inspecting and determining virtual screening hits.
Thirty one hits were chosen to be tested in vitro.

2.2.

Surface Plasmon Resonance
SPR analysis was performed using a Biacore T100 workstation (GE Healthcare,

NJ, USA). A recombinant form of the CD81-LEL protein with a GST-tag (Shoshana Levy
Lab - Stanford) was used to determine the binding affinities of the 31 ligands. 10 uM
CD81-LEL-His diluted into 10 mM sodium acetate buffer pH 4.5 was immobilized for 15
min at a flow speed of 5 ul/min onto a CM5 sensor chip using amine coupling (EDCNHS). Approximately 20,000 RU of protein were immobilized on the chip. The ligands
were prepared as 200 uM solutions in PBS-1% DMSO (the running buffer) and they were
introduced to the protein using a pre-programmed 3 min association and 1 min
dissociation interval.
2.3.

Antibody Neutralizing assays
For antibody neutralization assay Raji cells were used, a human B cell line that

expressed high amounts of CD81 on the surface (data not shown). Cells were grown in
RPMI medium (10% FCS, 1% penicillin/streptomycin, 1% L-glutamine, 1% nonessential amino acids, 1% sodium pyruvate, pH 7.4, at 37oC with 5% CO2). 2x105 cells
were incubated with or without different concentrations (50 µM, 100 µM, 400 µM and 1
mM) of indicated inhibitor for 20 min at room temperature, subsequently 1 ul (16 ng/µl)
of FITC-labeled anti CD81 antibody (BD Pharmingen, 551108) was added to the cells
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and incubated for 20 min (antibody titration was performed to obtain a working dilution
range, data not shown). Cells were washed and analyzed by FACS (BD FACSCalibur,
software: Cell Quest Pro). Mean Fluorescence Intensity MFI was calculated using Flowjo
software (TreesStar, www.flowjo.com).
2.4.

Mosquito Infection
Anopheles stephensi mosquitoes were fed on mice infected with Plasmodium

yoelii 17XNL parasites. On day 14 post bloodmeal, salivary glands were harvested,
homogenized, sporozoite number was determined using a hemocytometer and the
indicated number of sporozoites was added to cell monolayers. Plasmodium falciparum
sporozoites were generated by membrane feeding An. stephensi mosquitoes using
gametocyte cultures generated in vitro.
2.5.

Cells and antibodies.

HepG2-CD81 cells (8), which are derived from human liver carcinoma and express
CD81, were maintained in DMEM supplemented with 10% fetal calf serum and 1 mM
glutamine (DMEM/FCS). Monoclonal antibody (mAb) 2E6 was used for development
assays and is directed against Plasmodium Hsp 70 (9) and mAb 2A10 is directed against
the repeat region of P. falciparum CSP and was used for invasion assays.
2.6.

Invasion and development assays.

5 x 105 HepG2-CD81 cells were plated on collagen coated Lab-Tek wells and allowed
to adhere overnight. The following day, cells were preincubated with 400 uM of
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compound for 30 minutes at 37oC. Controls were pre-incubated with DMSO at the same
concentration in which it was found in the compound solutions. 105 sporozoites were
added to each well and in the case of P. falciparum, incubated for 1.5 hours and scored
for invasion whereas in the case of P. yoelii, incubated for 44 hours and scored for
exoerythrocytic stages.
3. Results
Eight out of 31 ligands were found to bind to CD81 using surface Plasmon
resonance based assays (Table 1 – Figure 3). Ligand 87504 was found to be the one with
the most desirable binding-dissociation behavior having the highest binding RUs. Ligand
90444 and 93033 are considered of comparable binding and dissociation.
In addition, the eight ligands had inhibitory effect on CD81: antibody interaction
(Table 2). As shown, they were found to have a better inhibitory effect at concentration
of 400uM when compared to that of 100uM.
When sporozite infection assays were conducted with the ligands, four ligands
were found to inhibit P. yoleii (7962, 73735, 90444 and 75866) whereas ligand 40614
exhibited an interesting action where it enhanced the infection with P. yoelii (figure 4).
Inhibition of P. berghei by both ligands 7962 and 73735 was detected when using Hep16 hepatoma cells whereas 90444 and 75866 didn’t inhibit P. yoleii or P. berghei in Hepa16 cells. Ligand 40614 was found to be consistent in enhancing development in both P.
yoleii and P. berghei in both Hepa1-6 and Hep2G cells (figure 5). As for the infection by
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P. falciparum, 7962 and 73735 were found to inhibit the infection with this species. On
the other hand, 40614 wasn’t found to enhance infection with Pl. falciparum (figure 6).
During our in silico analysis of the binding modes of 7962 (the most promising
drug lead among the five tested compounds), we found that there are a number of 7962
conformations that interacted with the 21 amino acid sequence and Asp137 that were
known to be important for malaria infection (figure 7). As for 73735, some conformations
interacted with the peptide sequence and others bound near Asp137 (figure 8). The
majority of 40614 ligand conformers did not interact with the peptide sequence nor near
Asp 137. Only two 90444 ligand conformers were found to bind (weakly) nearby the
peptide but not close to Asp137. As for 75866, only few 75866 ligand conformers were
found to bind nearby the peptide sequence but none were found to bind near to Asp137.
Upon calculating the percentage of infection inhibition of the 3 Pl. species by the
five ligands, 7962 was found to exhibit a 100% inhibition of all 3 species whereas 73735
was found to possess an inhibitory percentage of 96.8%, 77%, and 82.3% of infection
with P. falciparum, P. yoleii and P. bergeii respectively.
4. Discussion
Upon conducting virtual screening runs, 31 ligands were selected to be the first set
for conducting experimental validation using surface Plasmon resonance. Eight of the
virtual screening hits were found to bind to CD81 using surface Plasmon resonance.
Ligand 87504 was one of the ligands that showed best binding and dissociation thus when
going back and analyzing it’s in silico binding behavior it was found to bind to several
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residues in the stretch of 21 amino acid residues identified by Yalouli et al. (7) to be
involved in Plasmodium : CD81-LEL interaction (figure 1).
Those eight ligands were further tested using antibody neutralizing assays and
were found to inhibit anti-CD81 binding to CD81-LEL in a dose dependent manner where
the 400uM concentration gave better inhibitory effect compared to the 100uM of the
ligands ranging from % of inhibition of 17% to ~30%.
There are three features of 7962 and 73735 (ligands that block sporozite infection)
that docking experiments suggest may distinguish them from 40614, 90444 and 75866
(ligands that do not block infection): (i) 7962 and 73735 conformers, in general, bind more
strongly to CD81 (1-3kcal/mole). (ii) The strongest binding conformers of 7962 and
73735 were found to bind to the red site A (figure 7, Figure 8). (iii) The higher number of
7962 and 73735 conformers are predicted to bind to or nearby Asp137; where none of the
40614, 90444 or 75866 conformers were predicted to bind near or to Asp137 which was
shown to be essential for infection. Collectively, these data suggest that ligand 7962 would
help generate a promising drug to treat several species of malaria.
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6. Figures
Figure 1. Stretch of 21 amino acid residues involved in plasmodium sporotzoites:
CD81-LEL interaction. Red, Green, Blue: amino acids surrounding three main ligand
binding sites. Light orange: V135-D155 - Dark orange: D137 (7).
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Figure 2. The 3 sites chosen on CD81-LEL to undergo virtual screening runs. Those
sites were based on the stretch of 21 amino acids where the site containing those residues
was fragmented into 3 subsites and each of them included other residues.

Site
3
Site
1
Site
2
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Figure 3. Bar chart representing the change in response units of the ligands that were
found to bind to CD81-LEL using surface Plasmon resonance. The chart shows that
87504 had the best binding – dissociation behavior with CD81-LEL whereas 90444 had
the least desirable binding-dissociation behavior.
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(a)

Figure 4. Inhibition of P. yoelli Infection of HepG2 Cells. Ligand 7962 was found to
have the strongest inhibitory effect followed by ligand 73735, 75866 and 90444. Ligand
40614 was found to enhance the infection with Pl. Yoleii in HepG2-CD81(a). The gliding
Assay(b).

(b)
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(a)

Figure 5. Inhibition of P. yoelli & P. berghei Infection of Hepa1-6 Cells. Ligands were
tested using Hepa 1-6 cells which express less CD81 so as to see the difference in behavior
compared to HepG2 cells that express higher no. of CD81…It was found that both
Ligands 7962 and 73735 exhibited an inhibitory effect yet, ligands 90444 and 75866
didn’t show any inhibitory effect in case of Plamodium yoleii (a) and Plasmodium berghei
(b).
(b)
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Figure 6. Comparison of Inhibition of P.y. and P.f. Infection of HepG2 Cells. The
results of ligands tested using HepG2 cell line (a) were compared to its effect on infectivity
of P.y and P.f. It was shown that ligands 7962 and 73735 affect the invasion step and not
post invasion whereas ligands 90444 and 75866 affects steps other than invasion where
in case of P.f. invasion is the only step observed (parasites inside ersus outside of the cell).
40614 does not enhance infection in Pf (may affect post invasion event) (b).

(a)

(b)
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Figure 7. The different binding modes of 7962 to CD81. A number of 7962
conformations interacted with the 21 amino acid sequence and Asp137 that were known
to be important for malaria infection.
(a)

(b)

(c)
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Figure 8. The different binding modes of 73735 to CD81. A number of 7962
conformations interacted with the 21 amino acid sequence and Asp137 that were known
to be important for malaria infection.
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7. Tables
Table 1. Surface Plasmon Resonance Experiment. This table shown the change in
response units in relation to binding and dissociation of the 8 ligands that were tested.

Ligand ID
87504
40614
7962
30930
98026
75866
93033
90444

Binding (RU)
72
52.5
43.6
38.6
36.6
14.3
6.7
-1.7

Dissociation 1 (RU)
57.9
50.8
14.7
26.8
35.9
18.9
16.8
13.1

Dissociation
(RU)
42.6
43
10.1
21.8
28.1
11.3
7.9
5.6

2
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Table 2. Percentage of infection inhibited by the 5 tested ligands in the 3 Plasmodium
sp. Two cell lines were used to show the reduction in infectivity of Pl. sporozoites (HepG2
cells and Hepa 1-6)

Ligand

Percent Infection
HepG2-CD81

Hepa1-6 Cells

P.f.

P.y.

P.y.

P.b.

73735

3.2

23

38.3

17.7

90444

98.7

44.3

222

95.6

7962

0

0

0

0

40614

86.2

234

238

167

75866

84.2

42.6

122

135
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CHAPTER VIII
CONCLUSIONS
AutoDock and its tool AutoLigand proved to be very helpful in identifying
potential ligand binding sites on the surface of CD81-LEL. In addition to generating fill
points for each cavity and using the collective points to provide information about the
volume and depth of the cavity, a feature common to most docking programs, properties
were identified for specific point groupings (features equivalent to atoms or functional
groups) that would optimize the ligand’s interaction with specific atoms lining the inner
surface of the cavity. Using AutoLigand, we also increased our efficiency of identifying
new molecules that bound to the protein. Previous studies using earlier versions of
AutoDock that did not contain AutoLigand yielded results in which 25-55% of predicted
binders actually bound to the target protein when tested experimentally. The virtual ligand
screens (docking runs) performed in this study led to the identification of a diverse group
of new small molecules that bind to CD81-LEL. A set of 36 ligands were tested by SPR
and DPI to obtain a set of 26 new molecules we can use to develop inhibitors that block
HCV invasion. Four of these ligands were observed to exhibit stronger or similar binding
to CD81-LEL as benzyl salicylate, a small molecule reported to be a moderate inhibitor
blocking the binding of HCV E2 to CD81. One of these ligands, 689002, has been found
to inhibit the binding of HCV E2 to CD81-LEL. 689002 and the other ligands identified
in this study will be used to develop second generation leads that bind more tightly to
CD81-LEL using fragment-based drug design methods, and different combinations of Site
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1 and Site 2 ligands will be linked together to create selective high affinity ligands called
SHALs.

Two ligands, 689002 and 93033 were linked together to form a bidentate SHAL
(SH7153). Using SPR analysis, SH7153 was found to bind to CD81-LEL when tested
using SPR. But flow cytometry assays and HCV infection inhibition assays showed that
SH7153 didn’t have an inhibitory effect. This might be either due to the length of linkers
which might need optimization or exchanging one of the two ligands with a new ligand
that shows better binding mode in silico.

HCV E2 glycoprotein has a major role in the viral entry and its pathogenic effects
being involved in different interactions with different host factors. Several research groups
targeted different HCV proteins like serine protease and polymerase. The availability of
the core structure of HCV E (E2c) (12) makes it feasible to generate a drug that targets
the early stage of HCV via blocking HCV E2 interaction with different host factors.
Although E2 has several hypervariable regions where HVR1 is highly mutative, targeting
conserved residues in HCV E2 might help generate a drug that treats several HCV
genotypes and subtypes.

In this study a structural model of the HCV E2 protein has been created using the
E2c crystal structure as a template. Docking studies conducted with this model have led
to the identification of 23 small molecule drug candidates that bind to the E2 protein. We
were able to identify a new drug lead, 281816, which was found to inhibit HCV genotypes
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and subtypes (1a, 1b, 2a, 2b, 3, 4a and 6a). This new drug lead might offer a new paradigm
in HCV treatment. It might also be interesting to develop a cocktail of drugs that target
E2 binding site on CD81 and CD81 binding site on E2, hence completely blocking the
HCV E2: CD81 interaction and downstream pathogenic effects.
In several studies, SHAL were shown to increase the binding affinity when
compared to single ligands. Hence, an in silico bidentate SHAL (SH2216) based on the
studies on HCV E2 model was designed in silico. 281816 was shown to bind to several
potential binding sites on the created homology model that comprises several significant
residues such as PRO619 and TRP613. Owing to the fact that 281816 doesn’t have neither
free amino group nor free carboxyl group, a search for an analogue that do have one of
these groups was conducted. Ligand 22594527 was found to have a free amino group. It
was docked to the model to compare its binding modes to that of 281816 and it was found
to have the same desirable binding to HCV E2. Two binding sites were chosen and the
distance between the aminogroup of the first ligand and that of the second between the 2
sites was measured and an in silico designed SHAL was designed accordingly linking the
2 ligands with mini-PEG and lysine moieties.
Knowing that CD81 is a common target for HCV and malaria, we identified the
significant residues involved in plasmodium sporozoite: CD81 interaction that are
responsible for sporozoite invasion into the hepatocytes based on previous research done.
We targeted those residues using AutoDock and did virtual screening runs against a
library of ~4000 ligands. Eight out of thirty one ligands tested using surface Plasmon
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resonance were found to bind to CD81. They were further tested using antibody
neutralizing assays to see which inhibit binding CD81 to JS-81 antibody. They were also
found to inhibit the JS-81: CD81 binding. Upon testing 5 of them using sporozoite
invasion assay, Ligands 7962 and 73735 were found to inhibit P. falciparum, P. yoleii and
P. berghei at 400uM conc.
Collectively, the approach adopted throughout the PhD project depended on
determining virtual screening hits based on in silico analysis of the virtual screening
results, testing them using surface Plasmon resonance to confirm binding to the target
protein, followed by antibody neutralizing assays to validate that they may have an
inhibitory effect of the infection and ending with infection inhibition assays and
sporozoite invasion assays.

177

CHAPTER IX
FUTURE PERSPECTIVES
A library of promising compounds resulted from this study and this in turn
necessitates the continuation of analyzing other subsets of these compounds for binding
either to CD81 or HCV E2. Additionally, the drug leads that were already identified
should be further tested in cell culture and animal models to be able to conduct
pharmacokinetics and pharmacodynamics studies.
Since generating SHALs is considered a beneficial approach when it comes to
increasing the binding affinity to the target protein. Selecting different hits against CD81
and generating a cocktail of bi-dentate and tridentate SHALs from them would help come
up with a better drug candidate; since as the number of ligands increase in a SHAL, the
binding affinity increase (Bi-dentate  Tri-dentate). It would also be helpful to try
different lengths of the linkers in SH7153 so as to see whether the non-inhibitory effect
was attributed to the linkers’ length being not suitable or to the included ligands
themselves (689002 and 93033).
281816, one of the promising drug leads was found to inhibit HCV in a genotypeindependent manner. Testing it using a suitable HCV animal model would help take a step
further towards confirming if this is a suitable drug candidate for the treatment of HCV.
Additionally, it might be useful to synthesize SH2216 based on the in silico designed one,
test it and compare its inhibitory effect to that of 281816 alone. It would also be interesting
to test other 281816 analogues (figure 1) to observe their inhibitory effect as well.
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The identified drug leads that are targeting the plasmodium sporozoite: CD81
interaction should be further tested using sporozoite invasion assay. This will help identify
the best inhibitors and optimize them further to be suitable drug candidates.

179

Figure 1. 281816 analogues that were found to be FDA approved for treating
different diseases.

zinc93
1
C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
Amoxapine (211µM)
Amitriptyline
CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31

Loxapine
CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl

zinc968257

zinc1639

Quetiapine
C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42

zinc19632628
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Table 1. The 281816 drug analogs and their corresponding indications
Analog/Drug

Indications

Amoxapine
Amytryptiline
Loxapine
Quetiapine

Antidepressant
Tricyclic antidepressant
Typical Antipsychotic
Atypical Antipsychotic
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CHAPTER X
NOVELTY
The novelty of the work done in this thesis project lies in targeting the entry phase
of HCV instead of the replication and translation process which is targeted by polymerase
and protease inhibitors. The aim of this project was to identify drug leads that have the
ability to block the entry phase of HCV via blocking HCV E2: CD81-LEL interaction and
thus altering any upstream processes. The two main protein targets that were used were
CD81-LEL and HCV E2. In case of HCV E2, a homology model was created based on
the newly resolved crystal structure of the core of HCV E2 (E2c) (PDB ID: 4MWF), and
this was further used in virtual screening to identify potential hits that could block the
entry phase. This helped identify a promising drug lead (281816) that was found to block
HCV infection and cell to cell transmission. On the other hand, specific residues in CD81LEL that were known to interact with HCV E2 from previously published literature were
targeted so as to identity additional set of hits that could block the entry phase.
Beside targeting HCV, CD81-LEL was known to be involved in malaria infection
through interacting/facilitating the internalization of the Plasmodium sp. Sporozoites
invasion into the hepatocytes. Accordingly, we targeted the specific residues in CD81LEL that were known to be involved in internalization of malaria sporozoites. This in turn
led to the identification of 2 drug leads that were found to exert inhibitory effects on Pl.
falciparum which is one of the most aggressive human plasmodium parasites.
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